

This manuscript is part of an upcoming journal supplement about the control and elimination of *Plasmodium vivax* malaria.

In order to provide our readers with timely access to new content, papers accepted by the American Journal of Tropical Medicine and Hygiene are posted online ahead of print publication. Papers that have been accepted for publication are peer-reviewed and copy edited but do not incorporate all corrections or constitute the final versions that will appear in the Journal. Final, corrected papers will be published online concurrent with the release of the print issue.

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

BAIRD AND OTHERS

DIAGNOSIS AND TREATMENT OF VIVAX MALARIA

Diagnosis and Treatment of *Plasmodium vivax* Malaria

J. Kevin Baird,^{1,2*} Neena Valecha,³ Stephan Duparc,⁴ Nicholas J. White,^{2,5} and Ric N. Price^{2,6}

¹Eijkman-Oxford Clinical Research Unit, Jakarta, Indonesia; ²Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom; ³National Institute for Malaria Research, New Delhi, India; ⁴Medicines for Malaria Venture, Geneva, Switzerland; ⁵Mahidol Oxford Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand; ⁶Division of Global and Tropical Health, Menzies School of Health Research—Charles Darwin University, Darwin, Australia

* Address correspondence to J. Kevin Baird, Eijkman-Oxford Clinical Research Unit, Jalan Diponegoro No. 69, Jakarta 10430, Indonesia. E-mail: kevin.baird@ndm.ox.ac.uk

Abstract.

The diagnosis and treatment of *Plasmodium vivax* malaria differs from that of *Plasmodium falciparum* malaria in fundamentally important ways. This article reviews the guiding principles, practices, and evidence underpinning the diagnosis and treatment of *P. vivax* malaria.

DIAGNOSTIC PRACTICES FOR *PLASMODIUM VIVAX* MALARIA

Infection.

The diagnosis of *Plasmodium vivax* infection can be broadly categorized into three purposes: identification of clinical cases (passive case detection [PCD]), surveillance (active case detection [ACD]), and clinical trials. Each scenario brings distinct requirements, tools, and pitfalls for diagnosis of the infection.

Passive case detection.

The accurate diagnosis of vivax malaria in an acutely ill patient seeking routine care requires microscopy examination of a Giemsa-stained blood smear (microscopy), or use of an immunochromatographic cassette containing monoclonal antibodies to a *P. vivax* antigen (rapid diagnostic test [RDT]). Clinical signs and symptoms alone, though frequently used, can neither differentiate malaria infection from other causes of febrile illness, nor distinguish between *Plasmodium falciparum* and *P. vivax* or malaria caused by another plasmodia. Competent microscopy is typically more sensitive, specific, and informative (with respect to parasite count and stages present) than RDT. However, the sustainability of microscopy services challenges most health-care systems where endemic malaria occurs.^{1,2}

Microscopy.

Standards for malaria microscopy training, certification, and practice are available from World Health Organization (WHO).^{3,4} Examination of at least 200 fields of a thick blood film under oil immersion magnification ($\times 1,000$) should be undertaken before a negative diagnosis is made. The limit of detection for expert microscopists is considered to be about 10–20 parasites/ μL .^{5,6} Routine competent microscopy in clinical settings is considered unreliable below about 50 parasites/ μL .

The density of parasitemia in patients with acute vivax malaria depends upon many factors, including naive versus a state of semi-immunity, age, delay in seeking treatment, self-treatment behavior before presentation, and likely a variety of host and parasite factors.⁷

The parasite density in *P. vivax* malaria is typically an order of magnitude lower than *P. falciparum* in most clinical settings where both these species occur, thus increasing the risk of false negative microscopy diagnosis with acute vivax malaria. Repeated blood film examinations, or increasing the number of microscopy fields to 300 or more in patients suspected of having malaria should be carried out before confidently reporting the patient as negative for malaria parasites.

The primary diagnostic threat in the clinical setting is poor sensitivity. Training of clinical microscopists should be aimed at maximizing parasite detection, even if that is at the cost of a lower level of specificity. In some settings where vivax malaria predominates and transmission of *P. falciparum* is falling, there may be particularly low sensitivity for *P. falciparum*.

In addition to relatively intensive training and certification for the microscopist, competent microscopy requires a clean and well-functioning light microscope, clean glass slides, immersion oil with appropriate optical properties, and fresh filtered reagents for Giemsa staining. In many settings of endemic malaria, these essentials represent substantial challenges that cannot be reliably sustained. Where the quality of microscopy services cannot be assured, the use of RDT is recommended.⁸

Rapid diagnostic tests.

The principle advantage of RDTs is their ease of use and sustainability in resource-challenged settings. RDTs are available from many commercial sources at relatively low cost (usually $< \text{US\$1/test}$). Most of these kits are stable at ambient temperature storage for many months. WHO offers standards for training and certification in the use of RDT.⁹ The sensitivity and specificity of RDT varies greatly among commercial providers, and by species being diagnosed. In general, the kits perform better with *P. falciparum* infection than that with *P. vivax* (e.g., 74% versus 37% of test brands scored $> 75\%$ “parasite detection score” at a density of 200 parasites/ μL , respectively¹⁰). However, among the several dozen tests evaluated, a dozen scored $\geq 90\%$ on the parasite detection score for *P. vivax* and *P. falciparum* at 200 parasites/ μL . These kits may be viewed as suitable for the diagnosis of acute vivax malaria by RDT (see Table 1). Some tests detect *P. falciparum* histidine-rich protein 2 in addition to a pan-genus antigen (lactate dehydrogenase [pLDH]). Reaction to both indicates presence of *P. falciparum*, either alone or mixed with any other species, whereas reaction to pLDH alone indicates absence of *P. falciparum* and presence of

any other species, but does not distinguish among these. Other RDTs do offer a *P. vivax*-specific diagnosis employing aldolase antigen capture with satisfactory performance.¹¹

Active case detection.

ACD is usually conducted through mass blood surveys with the intent of detecting asymptomatic carriers of infection for the purposes of either malaria control or measurement of prevalence of parasitemia in at-risk populations. Asymptomatic carriers typically have much lower parasitemias compared with those seeking medical attention for illness, and RDTs detect only a minority of these infected individuals. The majority of mass blood surveys (historically and today) are performed using microscopy. The growing realization of the importance of detecting low-level parasitemias has spurred development of alternative technologies such as loop-mediated isothermal amplification (LAMP) and polymerase chain reaction (PCR).^{12–15}

Microscopy.

The process of microscopy for the purpose of ACD is similar to that described for PCD. A microscopist has some flexibility in the clinical setting regarding the degree of effort committed to an examination (e.g., > 200 fields and multiple smears examined for a single patient). However, in ACD, only one blood film is usually collected, and thus care must be taken to ensure that the same degree of diligence is applied for all samples collected.

Polymerase chain reaction.

The most widely applied and validated molecular diagnostic is a nested PCR amplification of small subunit ribosomal RNA gene sequences.¹⁶ The term nested refers to an initial amplification using primers of genus-wide sequences followed by primers of species-specific character to provide the definitive diagnosis. This technique, and other PCR-based approaches to diagnosis, requires relatively advanced laboratory equipment and technologically skilled execution. Typically, blood blots dried onto filter paper in the field are transported to a laboratory where extraction of DNA and its analysis by PCR is performed. It is also relatively expensive. The advantage of PCR is increased sensitivity to detect parasitemias up to three orders of magnitude lower (depending on blood volume sampled) compared with microscopy or RDT. Its absolute sensitivity in operational use is approximately 1.0 parasite/μL, increasing to 0.02 parasites/μL if > 0.25 mL of venous blood can be collected.

Loop-mediated isothermal amplification.

LAMP of parasite-specific DNA is a more recent technology more suited to ACD in endemic settings. The technique does not require expensive thermocyclers or gel electrophoresis, the readout being a visual color change in a small test tube. Recent evaluation of a commercially available kit (with *P. falciparum* and pan-genus-specific reagents) showed the technique to be comparable to standard nested PCR technique and superior to expert microscopy.^{17,18} The procedure can be completed in about 1 hour at the site of collection. A modified LAMP procedure, as well as standard nested PCR, was performed in the diagnosis of *P. vivax* in large field surveys in China.¹⁹

Serology.

Diagnostic techniques employing serological markers have been applied mostly to studies of protective immunity and epidemiology. Most published studies have applied techniques using antigens derived from synthetic peptide vaccine candidates rather than those that may be more informative of active or latent infection. Studies of the vaccine antigen–derived serological assays generally show very poor specificity with regard to diagnosis of active infection. Further work aimed at antibodies specific to acute infection, rather than prolonged protection against such infection, is required and should have the potential to identify populations at greatest risk of parasitemia.

Glucose-6-phosphate dehydrogenase deficiency.

The diagnosis of glucose-6-phosphate dehydrogenase deficiency (G6PDd) is an important diagnostic procedure before initiating the radical cure of *P. vivax*, which currently requires administration of primaquine (PQ). PQ can cause serious hemolysis in patients with G6PDd, an inherited X-linked highly diverse disorder affecting about 400 million people. G6PDd occurs at a prevalence varying from < 1% to 30% among residents of endemic zones.²⁰ There are many distinct variants of G6PD enzyme each with different degrees of compromise of its key metabolic function—the provision of reducing equivalents via nicotinamide adenine dinucleotide phosphate (NADPH) and reduced glutathione in sustaining redox equilibrium of the cytosol and protecting cell constituents from oxidative damage.²¹ In most genotypes, the mutant enzyme degrades more rapidly, rendering the older red cells the most deficient. The residual enzyme activity defines a clinically relevant and measurable phenotype for many variants.

Because the G6PDd is X-linked, it is either wholly absent or present (hemizygous) in males. In females, in contrast, it may be absent, homozygous, or heterozygous. Homozygosity in females is relatively rare (the square of the allele frequency), but heterozygosity is common. This is an important clinical and diagnostic problem due to the phenomenon of lyonization of X-linked genetic traits in women. This process results in two distinct populations of red blood cells, that is, those expressing defective or normal G6PD. The relative proportion of cells expressing abnormal enzyme averages 50% but ranges between 0% and 100%. In other words, heterozygous females may be G6PD normal or fully G6PD deficient; however, most have red blood cell populations presenting a mosaic of the two phenotypes. The clinical significance of this in the context of PQ toxicity is unclear, but challenges the widespread deployment of PQ to vulnerable populations.

Clinical diagnosis.

Ascertainment of G6PDd status in a clinical setting can involve the quantitative or qualitative measurement of G6PD activity in hemolysate, cytochemical microscopic examination of whole cells, or inference from genotyping extracted DNA using PCR technology.

Quantitative diagnosis.

Standardized commercially available kits may be used for the spectrophotometric determination of G6PD activity in enzyme units (U) per gram of hemoglobin (gHb). Normal values range approximately from 7 to 10 U/gHb (at 30°C).²² The genetic heterogeneity of

phenotypically “normal” G6PD enzyme and varying environmental factors may account for the wide range of activity values.²³ Patients presenting values less than 7 U/gHb are classified as G6PD deficient. G6PD activity is usually defined as a percentage of normal activity, as this provides an intuitive measure of likely vulnerability to hemolytic anemia. The “normal” denominator of the estimation is usually defined by the mean G6PD activity of most patients evaluated in any given patient population. Table 2 lists validated quantitative assays and their commercial providers.

In the quantitative assay, as in the qualitative assay, diagnosis of G6PDd in patients having recently suffered acute hemolytic anemia is problematic, since some patients may exhibit a normal phenotype as a consequence of the most vulnerable red blood cells having been removed and their replacement by young erythrocytes that have inherently higher G6PD activity levels. The effects of acute malaria on G6PD tests have not been evaluated.

Most G6PD tests require a separate Hb measurement, and this imposes additional complexity and costs. The reason of doing so, however, is the impact of Hb level on the qualitative measurement, for example, below about 8 g/dL Hb, G6PD activity measurements trend sharply higher, probably falsely so.²⁴ G6PD activity measurements from anemic patients should not be considered reliable.

Qualitative.

Standardized commercially available kits allow a visual determination of G6PD phenotype. These all involve the enzymatic conversion of NADP⁺ to NADPH by G6PD, which may be visualized directly (using fluorescent lighting) or indirectly (using one of several azole dyes that change color in the presence of NADPH). The most commonly used and widely validated qualitative assays are listed in Table 2. An alternative option is the methemoglobin reduction assay.^{25,26}

Cytology.

Cytological techniques can be used to measure the degree of X-inactivation by lyonization in heterozygous females. These methods differentially stain individual red blood cells and permit estimation of the proportion of cells expressing defective G6PD enzyme. A variety of techniques have been described,²⁷ including a recent flow cytometry method of particular promise for clinical and research settings.²⁸

Genetics.

The principal advantage of G6PD genotyping is a diagnosis un-confounded by the physiological variables affecting G6PD activity such as patients suffering acute hemolytic anemia or lyonization in heterozygous females. The primary disadvantage, however, is the uncertainty of a “normal” diagnosis when applying primers to selected known genotypes using standard PCR/restriction fragment length polymorphism (RFLP) techniques. The patient may be deficient but with a genotype not represented in the genetic analysis—a significant hazard with G6PD, which is a complex gene with over 200 known variants documented. New variants of G6PD are routinely found wherever sufficiently detailed investigations can be carried out.^{29,30} Although whole gene sequencing is certainly possible, it is currently impractical in a routine clinical sense due to its very large size (18.5 kb), complex structure (13 exons), and the occurrence of mutations all along its length. The most

commonly applied methodology is PCR/RFLP and requires specific selection of a number of mutation-specific primers limited by practicality.

Point-of-care and survey diagnosis.

Most patients with vivax malaria receive care at home or in the community outside of a clinic. Even when patients attend a clinic or hospital with a laboratory facility, there is often no capacity for G6PDd diagnosis. Similarly, diagnosis of G6PDd for survey purposes also occurs in rural settings and often cannot accommodate relatively sophisticated laboratory techniques.

Point-of-care diagnosis.

There is currently no validated point-of-care (POC) diagnostic device for G6PDd that is practical to apply where most malaria patients live. The obstacles to such a test include cost, complexity, heat sensitivity, and the need for a cold chain to transport and store the kit. A commercial kit in development, however, shows promise in overcoming those issues: the CareStart G6PD™ (AccessBio), which is affordable, easy to use, and is not sensitive to ambient temperature fluctuations. However, although it is capable of reliably detecting G6PD deficiency below 30% of normal activity,^{31,32} it is currently insensitive to milder deficiencies and most female heterozygotes, a limitation of other qualitative tests. Although promising, CareStart G6PD™ requires more thorough assessment before it may be recommended for routine diagnosis of patients before PQ therapy.³³

G6PDd survey.

Surveys to assess the prevalence of G6PDd are often undertaken where laboratory capacity is limited, the test readout being subjective and visually categorized into G6PD deficient, intermediate, or normal. A newer quantitative technique—WST8/1-methoxy-PMS—has been successfully used to survey populations with a quantitative enzyme activity readout. Dried blood blots collected in the field and kept refrigerated are returned to the laboratory for G6PD activity determination in a 96-well spectrophotometric assay format.^{34,35} The results correlate well with other standard techniques.

Clinical trials.

Evaluation of the safety and efficacy of therapies for acute vivax malaria, which necessarily includes both blood schizontocidal and hypnozoitocidal therapies, employs diagnostics for both the infection and G6PDd. Clinical trials of experimental therapies often demand higher standards of diagnosis than may be applied in routine clinical care, to provide greater assurance of subject safety and the precision of efficacy estimates.

Diagnosis of P. vivax and G6PDd for blood schizontocidal efficacy.

Trials of blood schizontocidal therapies typically only enroll patients with parasitemias above a certain threshold, to increase the likelihood that the associated fever is due to the infection. When parasitemias exceed 500/μL, almost any diagnostic technique will suffice. However, microscopy remains the method of choice for staging the parasite and documenting the parasite clearance.

Screening for G6PDd is required for PQ therapy in trials and experimental blood schizonticide, which do not have a demonstrated safety profile in G6PD-deficient patients.

Diagnosis of P. vivax and G6PDd for hypnozoitocidal efficacy.

The methodology of anti-relapse efficacy trials is challenging, but broadening enrollment criteria may be warranted to include those with subpatent infections. In this context, the use of highly sensitive diagnostic techniques such as LAMP may help to discriminate patient risk groups at enrollment. It is important to identify patients with G6PD variants known to be at high risk of severe hemolysis. Historically, the NADPH spot test (which identifies patients with < 30–40% of normal activity) has been used for this purpose, including a series of trials of PQ as primary prophylaxis in the past decade where subjects received large cumulative doses of this drug over prolonged periods.³⁶ Although valid concerns may be raised regarding insensitivity to milder variants and female heterozygotes, there are no documented cases of acute severe hemolytic anemia following PQ therapy and a classification as normal by the NADPH spot test. At least in the specific instance of PQ, this record of safe use with NADPH spot test screening argues in favor of good safety of this technique or those of similar diagnostic performance. Nonetheless, direct evidence of safety in this practice is lacking.

Diagnosis of recurrent parasitemia.

Clinical efficacy is defined by the clearance and recurrence of parasitemia. In most patients these occur at relatively low levels of patency, and thus expert microscopy is crucial in the assessment of blood films. In contrast to routine clinical microscopy, the microscopist serving clinical trials must undergo rigorous certification to minimize false-positive outcomes, which have potential to significantly underestimate clinical efficacy.³⁷ False negative (intolerable in clinical settings) is less important in the detection of recurrent parasitemia in asymptomatic individuals being routinely followed up. Confirmation of the microscopic diagnosis by PCR techniques is often performed weeks or months later. Though microscopy lacks sensitivity relative to PCR techniques, it is far more unambiguous, whereas false-positive PCR by contamination is a well-known pitfall.

TREATMENT PRACTICES FOR *P. VIVAX* MALARIA

The goals of antimalarial treatment in *P. vivax* are to reduce the immediate risk to the host, eradicate peripheral asexual parasitemia, prevent the recurrent infection, and interrupt the cycle of transmission.³⁸ The ability of *P. vivax* to form dormant liver stages, (hypnozoites) capable of causing relapsing infections weeks to months after the initial blood-stage infection, provides a major challenge to the complete eradication of parasites from the body. Since no single drug achieves all of these aims, a combination of antimalarials is required targeting a variety of specific key elements of the parasite life cycle.¹

Treatment of asexual erythrocytic stages of *P. vivax*.

Treatment of uncomplicated vivax malaria.

In areas where *P. vivax* is known to be chloroquine (CQ) sensitive, the WHO recommends 3 days of CQ or an artemisinin combination treatment plus 2 weeks of PQ

(provided the affected individual is not severely G6PD deficient).³⁹ CQ remains a first-line treatment in most parts of the world due to its wide availability, low cost, and long terminal elimination half-life. However, in co-endemic malarious areas, this necessitates a separate treatment approach for *P. falciparum* and *P. vivax*.

Most commonly used antimalarial drugs are also active against the asexual stages of *P. vivax*, the exception being the antifolates, which act slowly,⁴⁰ and are vulnerable to the rapid development of drug resistance.^{41,42} Mefloquine,⁴³ atovaquone + proguanil,⁴⁴ halofantrine,⁴⁵ piperazine,⁴⁶ artesunate,^{47,48} and pyronaridine,⁴⁹ all show good efficacy against chloroquine-resistant (CQR) *P. vivax* in clinical trials.

Artemisinin combination therapies (ACTs) are the treatment of choice for CQR *P. vivax*.⁴⁶ WHO-recommended ACTs include artemether–lumefantrine, artesunate–amodiaquine, artesunate–mefloquine, and dihydroartemisinin (DHA)–piperazine. A fifth ACT, pyronaridine–artesunate, has recently obtained a positive opinion from the European Medicines Agency for the treatment of *P. vivax* malaria, but it is not yet recommended by the WHO. Artemisinin in combination with effective partner drug have shown excellent cure rates in *P. vivax* infection.⁵⁰ ACTs with partner drugs with longer elimination periods provide incidental suppressive prophylaxis against relapse for about a month, but relapse risk thereafter remains relatively high.

The deployment of an ACT-based strategy permits a unified policy for treating both *P. falciparum* and *P. vivax* infections, offering a pragmatic approach with operational efficiencies.⁴⁸ A unified policy also decreases frequent issues of species misdiagnosis in routine practice. The rise and spread of CQR *P. vivax* has led to a number of countries adopting ACTs as first-line treatment for *P. vivax*. These include DHA–piperazine in Indonesia and Cambodia, and AL in Papua New Guinea, Solomon Islands, Sudan, Namibia, South Africa, and Vanuatu.⁵¹ Unified treatment policy also infers anti-relapse therapy for *P. falciparum*, where *P. vivax* is sympatric (see Drug Development for *P. vivax* section).

Treatment of severe vivax malaria.

Severe and fatal vivax malaria has been reported from Indonesia,^{52,53} Papua New Guinea,⁵⁴ India,⁵⁵ and Brazil.^{56,57} The main manifestations are anemia and respiratory distress,^{53,56,57,61,62} although series of patients with coma, shock, and renal and hepatic dysfunction associated with vivax malaria have also been described.^{55–57,61,62} *Plasmodium vivax* is very sensitive to artemisinin and its derivatives. In the absence of comparative drug trials, physicians have tended to adopt a similar treatment approach for severe vivax malaria as for severe falciparum malaria,¹ namely administration of parenteral artesunate, if unavailable, artemether, and if that is also not available then quinine, along with broad-spectrum antibiotic cover and supportive care.

Large-scale multicentered trials in patients in Asia and Africa have demonstrated clear superiority of intravenous artesunate over quinine in reducing case fatality rate in severe falciparum malaria.^{63,64} Intravenous artesunate also leads to a rapid clinical response in patients with severe vivax malaria,^{53,61} but there have been no randomized clinical trials in severe *P. vivax* malaria.

Specific antimalarial treatment recommended in severe vivax malaria includes the following in order of preference:

Artesunate: 2.4 mg/kg body weight, intravenously or intramuscularly given on admission (time = 0), then at 12 and 24 hours, and then once a day. This is the treatment of choice.

Artemether: 3.2 mg/kg body weight, intramuscularly given on admission, then 1.6 mg/kg body weight per day.

Quinine: 20 mg quinine salt/kg body weight on admission (intravenous infusion in 5% dextrose/dextrose saline over a period of 4 hours) followed by maintenance dose of 10 mg/kg body weight 8 hourly (maximum infusion rate 5 mg salt/kg/hour).

Parenteral antimalarials should be administered for at least 24 hours. Once the patient can accept oral therapy, full course of oral ACT should be given to the patients. Full details are available in the latest Malaria Treatment Guidelines.¹

CQR *P. vivax*.

The first reports of CQR *P. vivax* were published in 1989 from Australian travelers to Papua New Guinea,⁶⁵ and in 1991 as an endemic problem in Indonesia,⁶⁶ 30 years after the documentation of CQR *P. falciparum*. Although intrinsic differences in the transmission dynamics between these two species may account for much of the time lag, it is likely that this also reflects the inherent complexity of defining antimalarial treatment efficacy of *P. vivax*.⁶⁷ High-grade CQR *P. vivax* has been documented on the island of New Guinea, where patients treated with CQ have been observed to have early clinical deterioration requiring hospitalization, delayed parasite clearance, and early recurrent parasitaemia.^{46,68,69} Evidence for declining CQ efficacy against *P. vivax*, albeit to a lesser degree, has been reported from across the vivax-endemic world (Figures 1 and 2).^{70–72}

In vivo efficacy.

The WHO's protocols for the evaluation of antimalarial efficacy focus primarily on the treatment of *P. falciparum*. These guidelines have undergone extensive revision over the last 20 years, the more recent versions extending their scope to investigate the therapeutic efficacy against *P. vivax* infections. Current guidelines for assessing CQ recommend supervised treatment and follow-up for a minimum of 28 days, accompanied by measuring whole blood CQ and desethylchloroquine level at the day of failure. Recurrent infections during this period presenting with whole blood CQ plus desethylchloroquine concentration exceeding 100 ng/mL are considered as resistant irrespective of whether they are relapse, recrudescence, or reinfection.

A major confounding factor in interpreting clinical drug efficacy against *P. vivax* is an inability to distinguish reliably between relapse, recrudescence, or reinfection. A variety of methodologies have been developed for *P. vivax* with as few as three polymorphic markers proving to be sufficient to discriminate homologous from heterologous infections.^{73–76} However, recurrence of *P. vivax* genetically identical to the pretreatment isolate can occur from either a true recrudescence of the initial infection or a relapse from hypnozoites generated from the prior blood-stage infection^{74,77}; unsurprisingly molecular methods are unable to distinguish between these alternatives. Relapses are also commonly genetically heterologous. The confounding effect of relapsing infections varies considerably between geographical locations, both for the absolute risk of relapse and the timing at which these occur. In equatorial regions, 50–80% of patients can have a relapse starting within 3 weeks of the initial infection (if a rapidly eliminated drug is used for treatment), whereas in patients infected by temperate strains, the risk of relapse may fall to 5–20%, recurrences

occurring many months after the initial infection.⁷⁸ Major impediments to defining CQ resistance and common causes of misdiagnosis of CQ resistance and susceptibility come from multiple aspects (Table 3).

A recent review of the literature identified 135 prospective clinical trials of antimalarial efficacy against the erythrocytic stages of *P. vivax* monoinfection published between 1980 and 2013, of which full manuscripts were available for 124 studies. There have also been 28 case reports of CQ resistance. A complete list of these extracted data is available in Supplemental Annex A. In total there have been 121 treatment arms documenting the efficacy of CQ (enrolling 13,878 patients) and 21 treatment arms assessing the clinical efficacy of ACTs (artemether–lumefantrine, eight; DHA–piperaquine, seven; artesunate–sulfadoxine, three; and one each for amodiaquine–artesunate, pyronaridine–artesunate, and artemisinin–naphthoquine). CQ efficacy has been quantified at 97 geographical locations, of which 47 (48%) revealed reduced potential susceptibility (Figure 1 and Supplemental Annex A).

Ex vivo and molecular assays.

The in vitro assessment of parasite drug susceptibility has proven to be very useful in the investigation and mapping of drug-resistant *P. falciparum*; however, the development of similar tests in *P. vivax* is more challenging. Unlike *P. falciparum*, the parasite preferentially invades young red blood cells, limiting its reproductive capacity and ability to adapt in continuous in vitro culture.^{79,80} Without culture adaptation, the ex vivo assessment of drug susceptibility in *P. vivax* field isolates has been limited to clinical samples derived directly from the human host and subjected to short-term culture and drug exposure as exemplified by the schizont maturation test.^{79–82} The inability to sustain in vitro growth restricts analysis of field isolates to a single time point making an assessment of reproducibility difficult. Despite its limitations, the current schizont maturation assay has demonstrated utility in discriminating parasite populations with different degrees of CQR,^{83–85} characterizing drug susceptibility profiles of *P. vivax* to commonly used antimalarial drugs,^{86,87} and screening susceptibility to novel therapeutic agents.^{88–93} Development of methods capable of sustaining *P. vivax* in continuous in vitro culture will transform the current ex vivo assay, accommodating cryopreservation of field isolates to reduce the reliance on the analysis of fresh isolates.

The identification of a molecular marker of CQ resistance in *P. vivax* remains elusive. Early studies failed to show a strong correlation between *pvcr-t-o* and the CQR phenotype,^{84,94,95} although more recently interest has focused on the transcription level of *pvcr-t-o* and its overexpression.⁹⁶ A sequence polymorphism in *pvmdr1* conferring Y976F has been reported in a number of studies and may correlate with CQ resistance^{84,97}; however, since CQ resistance can occur in isolates with wild type *pvmdr1*, *pvmdr1* mutations are likely to be at best minor determinants of CQ susceptibility.^{84,98,99}

Treatment of liver stages of *P. vivax*.

Determinants of efficacy.

For over 60 years, clinicians, policy makers, and patients have relied on PQ, an 8-aminoquinoline, for the radical cure of *P. vivax*. Primaquine is the only licensed antimalarial

with proven hypnozoitocidal activity, but can result in significant hemolysis particularly in those with G6PDd.^{100,101} In view of the risk of adverse reactions, PQ dosing strategies are influenced more by concerns over toxicity than by their absolute efficacy. These concerns are particularly important in poorly resourced settings where routine G6PDd testing is often unavailable.

The predominant determinant of therapeutic efficacy appears to be the total dose of PQ administered rather than the daily dosage or duration of therapy.¹⁰² In an attempt to reduce potential toxicity, the WHO guidelines for the radical cure of vivax malaria currently recommends the use of a daily dose of 0.25 mg/kg/day (3.5 mg/kg total dose) PQ taken with food once daily for 14 days, coadministered with CQ or ACT depending on CQ sensitivity in the region.¹⁰³ In southeast Asia and Oceania, the same guidelines recommend a higher daily dose of 0.5 mg/kg (7.0 mg/kg total dose) in view of the high risk of relapses.

A recent review of the published literature identified 87 clinical trials presenting data on 59,735 patients enrolled in 156 treatment arms¹⁰⁴; the extracted data from these studies are presented in Supplemental Annex B. The median rate of recurrence in the 44 studies of very low dose of PQ (total dose ≤ 2.5 mg base/kg) was 25% (range: 0–90%) at 4–6 months, compared with 6.7% (range: 0–59%) in the 82 studies of low-dose PQ (total dose > 2.5 mg/kg to < 5.0 mg/kg). High-dose PQ regimens (total dose > 5.0 mg/kg) were assessed in 28 treatment arms, and were associated with a median recurrence rate of 0% (range: 0–15%) at 1 month. However, comparisons between dosing regimens need to be interpreted with caution, since they are confounded by the marked heterogeneity in study design, dose regimens, and idiosyncrasies of the endemic setting notably variable rates of reinfection.

The frequency and the timing of relapses are determined by sporozoite inoculum and parasite relapse phenotype, and this results in huge regional variation in the absolute risk of relapse independent of PQ efficacy.⁷⁸ A better indication of PQ efficacy requires comparison with a control arm in which patients receive no PQ, thus controlling for background reinfection and relapse patterns.^{105,106} There have been 18 published studies with control arms. Of these, the effectiveness of a very low-dose PQ regimen was no different from patients who did not receive PQ, whereas for the low-dose regimens, a significant difference was reported in half of the studies (overall odds ratio [OR]: 0.14, 95% confidence interval [CI]: 0.06–0.35, $P < 0.001$). Two studies enrolling 171 patients demonstrated high effectiveness of high-dose PQ compared with a control arm (OR: 0.03, 95% CI: 0.01–0.13, $P < 0.0001$). Two recent studies from Indonesia documented good efficacy ($> 95\%$) against relapse in *P. vivax* among soldiers followed for a year (without risk of reinfection) after directly observed high-dose PQ therapy either following¹⁰⁷ or concurrent with ACT.¹⁰⁸

Current guidelines recommend a 14-day course, but such prolonged courses of treatment can result in significant problems with adherence.^{109,110} Poor adherence to a 14-day course of unsupervised PQ is likely to have a major impact on its public health benefit. One study showed comparable efficacy of the 14-day course following strong health messaging and clear instructions for completion of the course in Afghan refugees in Pakistan.¹¹¹ Short-course, high-dose regimens have potential to increase patient adherence, and thus effectiveness,¹¹² but appropriately powered prospective multicentered randomized controlled trials are needed to assess the tolerability, safety, efficacy, and effectiveness of such alternative radical curative regimens against current best practice.

Primaquine-resistant P. vivax.

There is no evidence of resistance to therapeutic doses of PQ by hypnozoites of *P. vivax*. This may reflect the absence of the phenomenon or the extraordinary difficulty of gathering unambiguous evidence of it. Ingram and others¹¹³ described the process of doing so in assessing a patient in New Zealand who relapsed repeatedly despite high-dose PQ therapy. Other possible causes of therapeutic failure must be ruled out, principally 1) insufficient PQ quality, dose, adherence, absorption, or metabolism; 2) recrudescence due to CQ resistance, or inadequate therapy per above; and 3) reinfection after therapy. A loss-of-function cytochrome-P450 2D6 genotype resulting in inadequate metabolism of PQ is an important cause of therapeutic failure, as occurred among two *P. vivax* experimental challenge subjects.¹¹⁴

Safety considerations.

The most common serious adverse effect (SAE) following PQ is intravascular hemolysis associated with the passage of dark or black urine and mild jaundice. There are two potentially lethal consequences; life-threatening anemia and acute hemoglobinuric renal failure. From 69 studies and additional case reports (excluding data from mass treatment campaigns) that evaluated adverse events to PQ, no SAEs were reported in G6PD-normal individuals, with the possible exception of one psychotic reaction in an individual with undetermined G6PD status.¹¹⁵ The 191 SAEs that were reported were in 25 individuals who were assumed to be G6PD deficient and in 166 with proven G6PDd (139 of these were described in case reports). The incidence of SAEs in the known G6PD-deficient group was 11.2% (27/241). Of all SAEs, 11.5% occurred after a probable overdose of PQ (mainly in children), 75.9% with radical curative regimens of 15 or 30 mg daily for vivax malaria, and 12.6% after administration of 30 or 45 mg PQ in weekly prophylactic or radical curative regimens, or as a single-dose gametocytocide.

In total 15 deaths associated with PQ have been reported over the past six decades, of which 13 were from severe haemolysis.¹¹⁵ No deaths were reported from the mass radical treatments (MDA) in Jiangsu, China (> 28 million treated) or from the combined experience in Azerbaijan, Afghanistan, Tajikistan, and Democratic People's Republic of Korea (> 8 million). G6PD screening was not performed in these MDAs but hemolysis was anticipated and was observed, and so education was provided and health services reinforced during the drug administration. The reported deaths occurred mainly in countries with a minority of the global malaria burden, which raises concern about the generalizability of this estimate. G6PDd is known to be very rare in northern China and the Koreas for example. The nations of greatest risk—with significant burdens of *P. vivax* and highly prevalent Mediterranean or Mediterranean-like severe G6PDd variants²⁰—often have poor pharmacovigilance and mortality reporting systems. Further, patients not surviving PQ therapy may often be presumed to have died as a consequence of malaria, as occurred in at least two cases reported from Brazil.^{116,117} Primaquine therapy against relapse certainly has the potential to cause lethal hemolytic anemia, but the incidence of such events cannot be known in the absence of evidence gathered by deliberate and direct surveys.

Primaquine is underused. Several studies highlight that even in areas where PQ is recommended, in practice it is prescribed rarely.¹¹⁸ Some endemic countries recommend the use of PQ with warnings on its potential toxicity in G6PD-deficient patients, but most do

not.³³ The lack of an available POC G6PD test means that the practitioner who prescribes a radical curative course of PQ risks inducing potentially serious hemolysis if the patient is G6PD deficient. POC testing to identify those at hemolytic risk would greatly enhance safe deployment and thus use of PQ. It is also important to balance this risk (borne entirely by those patients who are G6PD deficient) with the benefits derived by all treated patients; each *P. vivax* episode is associated with malaria-related hemolysis and dyserythropoiesis and a cumulative risk of anemia. This contributes to impaired development, school and work performance, and in high-transmission areas to anemia-related deaths. Without prolonged monitoring over repeated episodes of malaria, the benefits of radical cure may not be appreciated.

If there is no available G6PD POC test, it is difficult to generalize on the correct approach to patient management. The risk versus benefit weighing depends on the prevalence and severity of G6PDd in the area, the degree of anemia, and the availability of blood transfusion (i.e., the risks) as well as the probability of relapse and the likely dose regimen required (the benefit). In some circumstances the assessment may favor withholding PQ, and in others it may favor starting the radical curative regimen after educating the patient about the possible risks and informing the patient that they should stop the drug if they fail to recover within 3 days, become ill, or their urine becomes red or black.

Known G6PDd.

The evidence of PQ safety in known G6PD-deficient subjects or patients is limited to just four of the many dozens of known G6PD variants (A–, Mahidol, Mediterranean, and Viangchan) and less than a couple dozen subjects. In general, variants with > 5% residual G6PD activity showed relatively mild and self-limiting hemolysis, whereas those with < 5% activity showed severe hemolysis. There is insufficient evidence on which to guide PQ therapeutic decisions based on known or suspected degree of G6PD enzyme impairment. Any diagnosis of G6PDd in a male hemizygote should be considered indicative of risk of serious harm and prompt withholding standard daily PQ therapy against relapse.³³ An alternative regimen, 0.75 mg/kg weekly for 8 weeks was demonstrated in the early 1960s to cause only slight hemolysis in otherwise healthy African–American men having A–G6PDd.¹¹⁹ This regimen became widely recommended for anti-relapse therapy in G6PD-deficient patients, as well as underpinning an earlier recommendation for the same dose administered only once as gametocytocidal therapy for *P. falciparum* malaria.^{120,121} However, the safety of the weekly regimen in non-A– variants was not established.^{122,123} Only very recently were 18 Cambodian men with G6PDd (17/18 with Viangchan variant) and acute *P. vivax* malaria given the 0.75 mg/kg PQ dose weekly for 8 weeks.¹²⁴ All hemolyzed steeply after the first dose, but not dangerously, except for one subject who required hospitalization and transfusion. Subsequent weekly dosing showed only slight hemolysis. All known G6PD-deficient men receiving the weekly regimen of PQ should be clinically monitored after the first and second dose of PQ for assurance of safety.

Females present a more complex and difficult therapeutic problem. Homozygous females carry two mutant X alleles and phenotypically mirror hemizygous males in having 100% defective red blood cell populations. Female heterozygotes possess both wild type and mutant G6PD phenotypes, expressed as mosaicism in their red blood cell populations.

Random inactivation of one or the other X chromosome during embryonic development results in variable proportions of wild type and mutant phenotypes among their red blood cells (a process called lyonization).¹²⁵ The net G6PD activity measured in the whole blood of heterozygotes thus represents the average of two distinct subpopulations of red blood cells. The vulnerability of the mutant subpopulation to PQ -induced hemolysis may be presumed to be complete. In other words, a female testing at 50% of normal G6PD activity will have approximately 50% of her red blood cells exposed to possible destruction by PQ.³³ The therapeutic problem arises with G6PD screening applying a 30% of normal activity threshold for identifying G6PD deficient by qualitative screening³³: females testing as normal with > 30% G6PD activity may nonetheless be vulnerable to steep and threatening hemolysis with PQ therapy. This imposes the necessity of caution and clinical monitoring for all females screened as normal by standard qualitative G6PD screening tests for at least the first week of therapy.

Radical treatment in special groups.

Children.

There are relatively few data on the safety of PQ in young children, but there is no indication that toxicity in children differs from that in adults. Thus PQ is recommended in young children above 6 months of age, and not in infants (because of lack of data, rather than evidence of toxicity).¹ However, since G6PDd is specifically associated with neonatal jaundice and kernicterus, PQ should definitely be avoided in the first month of life (and in any case is unnecessary as there are no hypnozoites in congenital vivax malaria). Tablets containing doses less than 7.5 mg (base) of PQ are often unavailable, so accurate dosing is difficult, which leads to both under- and overdosing. Since the mg/kg dosing variation is greatest in young children, studies are needed as a priority to assess PQ safety in these vulnerable age groups.

Pregnant women.

Primaquine is contraindicated in pregnancy because of the unknown G6PD status of the fetus and thus the risk of inducing intrauterine hemolysis. Excretion of PQ in breast milk is not known so caution should be exercised and preferably PQ should not be given. If PQ is prescribed to a lactating mother, the baby needs to be observed closely.

Human immunodeficiency virus-positive patients.

There is no specific information on the safety of PQ in this important patient group. Primaquine has been used as a second-line treatment (with clindamycin) of *Pneumocystis jirovecii* infections without apparent complications.

Drug interactions.

Primaquine is metabolized by monoamine oxidase to the biologically inert, but slowly eliminated, carboxyprimaquine, and via CYP₄₅₀ (predominantly 2D6) to reactive intermediates that mediate both the antimalarial effects and hemolytic toxicity. Theoretically, inhibitors such as quinidine, ketoconazole, paroxetine, and fluoxetine may reduce toxicity, but these predictions require further study. Historic examples of likely drug-drug interactions have occurred between pamaquine (a PQ precursor) and mepacrine

(structurally similar to CQ) impacting safety, and between quinine and CQ impacting efficacy against relapse.¹²⁶

DRUG DEVELOPMENT FOR *P. VIVAX*

Outside of Africa, *P. falciparum* and *P. vivax* commonly occur together; mixed infection is very common, and many patients with falciparum malaria harbor *P. vivax* hypnozoites that commonly cause relapse 3–8 weeks after the acute illness. The emergence of CQ resistance in many endemic regions, along with > 50% prevalence of hypnozoites of *P. vivax* in patients diagnosed and treated for *P. falciparum*, provides a strong rationale for a unified policy for therapy of uncomplicated malaria of any species.^{127,128} Hence, many of the schizontocidal drugs under development are now routinely tested against both dominant species of plasmodia.¹²⁹ In general, those with high potency against multidrug-resistant *P. falciparum* are also efficacious against *P. vivax*.¹²⁹ The greatest challenge for achieving radical cure is the development of new agents with hypnozoitocidal activity, which can be administered safely and effectively in short-duration treatment regimens.¹³⁰

Tafenoquine.

Tafenoquine (TQ; SB-252263 and WR 38605), is an 8-aminoquinoline with in vivo anti-hypnozoite activity. The mechanism of action of TQ, as for all the 8-aminoquinoline class of drugs, is unknown. TQ has a long half-life enabling radical cure treatment as a single dose.¹³¹ TQ has been shown to be well tolerated and efficacious in vivax malaria radical cure in patients without G6PDd. A phase III study is underway with at least 600 subjects without G6PDd randomized to one of three treatment arms, TQ/CQ, PQ /CQ, or CQ alone, in a 2:1:1 ratio. This will assess the superiority of TQ/CQ over standard doses of CQ alone.

Phase I and IIb studies have been conducted and phase III efficacy and safety studies are ongoing.¹³² The phase I safety study investigated the hemolytic potential of TQ in healthy subjects with G6PDd, as well as the safety and tolerability of TQ in acute *P. vivax* malaria patients with G6PDd. The objective of the phase I dose escalation study was to determine the safety (hemolytic potential) and tolerability of TQ in G6PD-deficient healthy subjects without the influence of disease-related confounding factors. For the initial dose escalation phase, G6PD-deficient heterozygous female healthy volunteers with enzyme activity range between 40% and 60% of the site median normal value were recruited.

Blocking 8-aminoquinoline hemolytic toxicity.

Current options for radical cure are dependent upon the 8-aminoquinolines. Compounds that are protective against the oxidative damage from PQ or TQ have potential for safe deployment and accessibility to radical cure. Novel assays exist to screen for such products, for instance an in vivo immunodeficient murine model transfused with human G6PD-deficient blood.

Methylene blue.

During the development of PQ in the late 1940s, one volunteer experienced deep hemolysis after a few 60 mg daily doses of the 8-aminoquinoline isopentaquine. Months later, however, when the same dose of isopentaquine was administered with an oral 500 mg

dose of methylene blue (MB; methylthioninium chloride), the subject completed the 14-day regimen without signs of hemolysis.¹³³ However, smaller daily doses of MB administered to G6PD-deficient African children with acute falciparum malaria resulted in slightly more posttreatment hemolysis than in G6PD-normal children.¹³⁴

MB is registered (as Proveblue[®]) as a solution for injection, 5 mg/mL for the following indication: treatment of medicinal and chemical products–induced methemoglobinemia. Methylthioninium chloride is indicated in adults and children above the age of 3 months. However, it is currently contraindicated in patients with G6PDd due to the risk of hemolytic anemia.

Early stage development indicates some signs of genotoxicity in cell-level gene mutation assays, but not in in vivo murine studies. MB carcinogenic potential in male mice and rats. There are no adequate data on the use of methylthioninium chloride in pregnant women, but studies in animals demonstrate reproductive toxicity. The potential risk for humans is unknown. Preliminary work in huSCID/G6PD mice showed no signs of hemolytic toxicity at up to 50 mg/kg (the human experiment mentioned above was 8.3 mg/kg). This compound is under investigation as an 8-aminoquinoline-induced hemolysis-blocking agent.

Bulaquine.

Bulaquine (BQ) is a prodrug of PQ and is believed to hydrolyze in the stomach to PQ. Clinical trials of BQ have failed to show that this agent is superior to PQ in terms of safety or anti-relapse efficacy for relapse and this role in clinical practice remains limited.^{135,136} One study reported BQ to be better than PQ in G6PD-deficient patients but this only included three subjects, and pharmacokinetic analysis was not available.¹³⁷

Tinidazole.

Tinidazole is a 5-nitroimidazole used for the treatment of amebiasis and giardiasis. In the *Plasmodium cynomolgi*/macaque relapsing malaria model, tinidazole cured one of six macaques studied with an apparent mild delay to relapse in the other five monkeys. The only study in humans was conducted in healthy G6PD-normal Thai adults with *P. vivax* infection. Subjects were randomized to treatment with either 2 g of oral tinidazole daily for 5 days or standard therapy with PQ (30 mg base per day for 14 days); all patients received CQ (at 25 mg/kg/day for 5 days). Six of the first seven subjects treated with tinidazole relapsed before day 63. The authors of this study concluded that tinidazole was ineffective in preventing relapse of *P. vivax* given at 2 g a day for 5 days concurrently with CQ. The macaque relapsing model appeared to predict correctly the outcome in humans.¹³⁸

Finding new molecules against relapse.

There is no reliable *P. vivax* liver-stage assay currently available to drive drug discovery; hence, the current strategy to identify novel compounds relies largely on a pragmatic approach and the application of surrogate assays. The current approach (outlined in Figures 1 and 2) consists of screening a very large number of compounds in a high-throughput *P. falciparum* blood-stage assay, and selection of the most likely candidates to be tested in a secondary lower throughput assays such as the *Plasmodium yoelii* liver-stage assay (Figure 7).¹³⁹ While liver schizontocidal activity against a rodent malaria is not

directly relevant for relapse, it has been used as a tool to prioritize compounds for screening in any low-throughput in vitro relapse assay. To date all compounds blocking relapse have shown to have causal prophylactic activity. A *P. cynomolgi* liver-stage assay¹⁴⁰ uses *P. cynomolgi* sporozoite infections of primary rhesus hepatocytes to generate, reproducibly, small parasite forms. The latter have been shown to reactivate in vitro, suggesting that they may be hypnozoites.¹⁴¹ This assay represents the focus of current hypnozoitocidal drug discovery efforts. Potential compounds identified by the *P. yoelii* assay are then tested further to find series with a better therapeutic ratio than PQ.

A *P. vivax* liver-stage in vitro assay is under development to replace the current model. The aim is to develop assays with a throughput that is sufficient to screen large libraries directly. The development of this assay as well as other tools to aid in the development of anti-relapse molecule have been reviewed elsewhere (see the article by Olliaro and others).

Analysis of over 5 million compounds from approximately 20 compound collections from the pharmaceutical and biotechnology companies, academic diversity collections, and diversity providers, generated around 25,000 compounds with activity against the blood stage of the parasite IC50s ranging from 1 to 3 μ M. The liver-stage activity of a selection of those hits was then assessed using the *P. yoelii* assay.¹⁴² Some of these chemical entities are now high priority for the Medicines for Malaria Venture and its partners, and are entering lead optimization and clinical development (see the following link for review: <http://www.mmv.org/research-development/rd-portfolio>).

Work has also been undertaken to evaluate the liver-stage activity of the current portfolio of schizonticidal compounds, with more than 50 anti-infectives currently in use or under development. Several of these antimalarials with schizontocidal activity in a *P. yoelii* liver-stage assay are currently being evaluated in the *P. cynomolgi* S assay for their potential effect on hypnozoites.

Progress in trying to identify potential new candidates as anti-relapse agents has been made; it is however important to note that beyond those mentioned here, there are no new compounds in the global malaria portfolio in preclinical development specifically for their anti-relapse activity. The first generation of compounds that have been specifically optimized based on their potential for anti-relapse activity is expected to enter preclinical development in 2014.

CONCLUSIONS

The treatment of *P. vivax* has changed little over the last 60 years although recent technological advances promise to deliver better, more sensitive and field-adapted diagnostics for parasitemia and G6PDd, and to identify novel antimalarial compounds. *Plasmodium falciparum* is resistant to CQ in most endemic regions. CQR *P. vivax*, although slower to appear than *P. falciparum*, is spreading throughout the endemic world. A unified treatment policy for malaria caused by any species of *Plasmodium* may offer significant individual and public health advantages over the current strategy that relies on CQ plus PQ. ACTs are highly effective against *P. vivax*, and the more slowly slowly-eliminated ACTs suppress the early relapses, but whether this reduces transmission in the long term remains to be proven. The most important potential chemotherapeutic means of interrupting transmission of vivax malaria will be radical cure and thus prevention of all future relapses by using a safe and well-tolerated hypnozoitocidal medication. Primaquine is the only

licensed hypnozoitocidal drug, but studies are underway to find more practical ways of deploying it. Renewed efforts are underway to develop alternative treatments for safer and more effective radical cure.

KEY POINTS

A unified treatment policy for malaria of any parasitological cause will confer significant individual, public health, and operational benefits in regions co-endemic for *P. falciparum* and *P. vivax*.

Slowly eliminated ACTs offer posttreatment prophylaxis against the first relapse of tropical strains of *P. vivax*, which in the short term reduces the risk of anemia and the transmissibility of the parasite.

Ensuring adherence to a complete course of PQ is the greatest challenge in the control of *P. vivax* malaria, and may be achieved by adopting short-course, high-dose regimens, although the safety of these regimens has not been established.

A robust bedside test for G6PD deficiency is urgently needed to define the toxicity profile of PQ and facilitate the safe deployment of anti-relapse therapy.

Received March 4, 2016.

Accepted for publication April 19, 2016.

Note: Supplemental annexes appear at www.ajtmh.org.

Financial support: This work was supported by the Wellcome Trust (B9JIXO for J. Kevin Baird). Nicholas J. White is a Wellcome Trust Principal Fellow, and Ric N. Price is a Wellcome Trust Senior Fellow in Clinical Science.

Authors' addresses: J. Kevin Baird, Eijkman-Oxford Clinical Research Unit, Oxford University, Jakarta, Indonesia, E-mail: jkevinbaird@yahoo.com. Neena Valecha, Epidemiology and Clinical Research Division, National Institute for Malaria Research, ECR, New Delhi, India, E-mail: neenavalecha@gmail.com. Stephan Duparc, Medical R&D, Medicines for Malaria Venture, Geneva, Switzerland, E-mail: duparcs@mmv.org. Nicholas J. White, Mahidol-Oxford Tropical Medicine Research Unit, Mahidol University, Bangkok, Thailand, E-mail: nickwdt@tropmedres.ac. Ric N. Price, Division of Global and Tropical Health, Menzies School of Health Research—Charles Darwin University, Darwin, Australia, E-mail: ric.price@menzies.edu.au.

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

REFERENCES

1. World Health Organization, 2015. *Guidelines for the Treatment of Malaria*. 3rd edition. Geneva, Switzerland: WHO.
2. http://www.who.int/tdr/publications/microscopy_detec_ident_quantif/en/. Accessed October 20, 2015.
3. World Health Organization, 2009. *Malaria Microscopy Quality Assurance Manual*. Manila, Philippines: WHO, Western Pacific Regional Office.
4. World Health Organization, 2010. *Basic Malaria Microscopy*. 2nd edition. Geneva, Switzerland: WHO.
5. Greenwood BM, Armstrong JR, 1991. Comparison of two simple methods for determining parasite density. *Trans R Soc Trop Med Hyg* 85: 186–188.
6. Wilcox A, 1960. *Manual for the Microscopical Diagnosis of Malaria in Man*. Washington, DC: U.S. Government Printing Office.

- <bok>7. Bruce-Chwatt LJ, 1980. *Essential Malariology*. London, United Kingdom: William Heinemann Medical Books Ltd.</bok>
- <bok>8. World Health Organization, 2010. *Parasitological Confirmation of Malaria Diagnosis: Report of a WHO Technical Consultation, Geneva, 6–8 October 2009*. Geneva, Switzerland: WHO.</bok>
- <bok>9. World Health Organization, 2009. *How to Use a Rapid Diagnostic Test (RDT): A Guide for Training at a Village and Clinic Level*. Geneva, Switzerland: WHO.</bok>
- <bok>10. World Health Organization, 2012. *Malaria Rapid Diagnostic Test Performance: Summary of Results of WHO Product Testing of Malaria RDTs, Round 1–4 (2008–2012)*. Geneva, Switzerland: WHO. 2012.</bok>
- <jrn>11. Abba K, Kirkham AJ, Olliaro PL, Deeks JJ, Donegan S, Garner P, Takwoingi Y, 2014. Rapid diagnostic tests for diagnosing uncomplicated non-falciparum or *Plasmodium vivax* malaria in endemic countries. *Cochrane Database Syst Rev* 12: CD011431.</jrn>
- <jrn>12. Okell LC, Ghani AC, Lyons E, Drakeley CJ, 2009. Submicroscopic infection in *Plasmodium falciparum*-endemic populations: a systematic review and meta-analysis. *J Infect Dis* 200: 1509–1517.</jrn>
- <jrn>13. Cheng Q, Cunningham J, Gatton ML, 2015. Systematic review of sub-microscopic *P. vivax* infections: prevalence and determining factors. *PLoS Negl Trop Dis* 9: e3413.</jrn>
- <jrn>14. Imwong M, Nguyen TN, Tripura R, Peto TJ, Lee SJ, Lwin KM, Suangkanarat P, Jeeyapant A, Vihokhern B, Hue DV, Dong LT, Nugyen TU, Lubell Y, von Seidlein L, Dhorda M, Pomnarate C, Snounou G, Malleret B, Renia L, Keereecharoen L, Singhasivanon P, Sirithiranont P, Chalk J, Nguon C, Hien TT, Day N, White NJ, Dondorp A, Nosten F, 2015. The epidemiology of subclinical malaria in southeast Asia: findings from cross-sectional surveys in Thailand-Myanmar border areas, Cambodia, and Vietnam. *Malar J* 14: 381.</jrn>
- <jrn>15. Hoyer S, Nguon S, Kim S, Habib N, Khim N, Sum S, Christophel EM, Bjorge S, Thomson A, Kheng S, Chea N, Yok S, Top S, Ros S, Sophal U, Thompson MM, Mellor S, Arie F, Witkowski B, Yeang C, Yeung S, Duong S, Newman RD, Menard D, 2012. Focused screening and treatment (FSAT): a PCR-based strategy to detect malaria parasite carriers and contain drug resistant *P. falciparum*, Pailin, Cambodia. *PLoS One* 7: e45797.</jrn>
- <jrn>16. Snounou G, Viriyakosol S, Zhu XP, Jarra W, Pinheiro L, do Rosario VE, Thaithong S, Brown KN, 1993. High sensitivity of detection of human malaria parasites by use of the nested polymerase chain reaction. *Mol Biochem Parasitol* 61: 315–320.</jrn>
- <jrn>17. Hopkins H, Gonazalez IJ, Polley SD, Angutoko P, Ategeka J, Asiimwe C, Agaba C, Kyabayinze DJ, Sutherland CJ, Perkins MD, Bell D, 2013. Highly sensitive detection of malaria parasitemia in a malaria endemic setting: performance of a new loop-mediated isothermal amplification kit in a remote clinic in Uganda. *J Infect Dis* 208: 645–652.</jrn>

- <jrn>18. Polley SD, Gonzalez IJ, Mohamed D, Daly R, Bowers K, Watson J, Mewse E, Armstrong M, Gray C, Perkins MD, Bell D, Kanda H, Tomita N, Kubota Y, Mori Y, Chiodini PL, Sutherland CJ, 2013. Clinical evaluation of a loop-mediated amplification kit for diagnosis of imported malaria. *J Infect Dis* 208: 637–644.</jrn>
- <jrn>19. Lu F, Gao Q, Zhou H, Cao J, Wang W, Lim CS, Na S, Tsuboi T, Han ET, 2012. Molecular test for vivax malaria with loop-mediated isothermal amplification method in central China. *Parasitol Res* 110: 2439–2444.</jrn>
- <jrn>20. Howes RE, Piel FB, Patil AP, Nyangiri OA, Gething PW, Dewi M, Hogg MM, Battle KE, Padilla CD, Baird JK, Hay SI, 2012. G6PD deficiency prevalence and estimates of affected populations in malaria endemic countries: a geostatistical model-based map. *PLoS Med* 9: e1001339.</jrn>
- <jrn>21. Cappellini MD, Fiorelli G, 2008. Glucose-6-phosphate dehydrogenase deficiency. *Lancet* 371: 64–74.</jrn>
- <jrn>22. Ardern JC, Edwards N, Hyde K, Jardine-Wilkinson C, Cinkotai KI, Power DM, MacIver JE, 1988. A proposal for further standardization of red blood cell glucose-6-phosphate dehydrogenase determinations. *Clin Lab Haematol* 10: 409–416.</jrn>
- <jrn>23. Modiano G, Battistuzzi G, Esan GJ, Testa U, Luzzatto L, 1979. Genetic heterogeneity of “normal” erythrocyte glucose-6-phosphate dehydrogenase: an isoelectrophoretic polymorphism. *Proc Natl Acad Sci USA* 76: 852–856.</jrn>
- <jrn>24. Satyagraha AW, Sadhewa A, Baramuli V, Elvira R, Ridenour C, Elyazar I, Noviyanti R, Coutrier FN, Harahap AR, Baird JK, 2015. G6PD deficiency at Sumba in eastern Indonesia is prevalent, diverse and severe: implications for primaquine therapy against relapsing vivax malaria. *PLoS Negl Trop Dis* 9: e0003602.</jrn>
- <jrn>25. Aminwero CE, Olatunji PO, 2007. Re-evaluation of methaemoglobin reduction as a screening procedure for glucose-6-phosphate dehydrogenase (G6PD). *Afr Med Med Sci* 36: 177–181.</jrn>
- <jrn>26. Sanpavat S, Nuchprayoon I, Kittikalayawong A, Ungbumnet W, 2001. The value of methemoglobin reduction test as a screening test for neonatal glucose-6-phosphate dehydrogenase deficiency. *J Med Assoc Thai* 84 (Suppl 1): S91–S98.</jrn>
- <jrn>27. Peters AL, Van Noorden CJ, 2009. Glucose-6-phosphate dehydrogenase deficiency and malaria: cytochemical detection of heterozygous G6PD deficiency in women. *J Histochem Cytochem* 57: 1003–1011.</jrn>
- <jrn>28. Shah SS, Diakite SA, Traore K, Diakite M, Kwiatkowski DP, Rockett KA, Wellems TE, Fairhurst RM, 2012. A novel cytofluorometric assay for the detection and quantification of glucose-6-phosphate dehydrogenase deficiency. *Sci Rep* 2: 299.</jrn>
- <jrn>29. Benmansour I, Moradkhani K, Moumni I, Wajcman H, Hafsia R, Ghanem A, Abbes S, Prehu C, 2013. Two new class III G6PD variants [G6PD Tunis (c.920A>C: p.307Gln>Pro) and G6PD Nefza (c.968T>C: p.323 Leu>Pro)] and overview of the spectrum of mutations in Tunisia. *Blood Cells Mol Dis* 50: 110–114.</jrn>
- <jrn>30. Sirdah M, Reading NS, Vankayalapati H, Perkins SL, Shubair ME, Aboud L, Roper D, Prchal JT, 2012. Molecular heterogeneity of glucose-6-phosphate

dehydrogenase deficiency in Gaza Strip Palestinians. *Blood Cells Mol Dis* 49: 152–158.</jrn>

<jrn>31. Baird JK, Dewi M, Subekti D, Elyazar I, Satyagraha AW, 2015. Non-inferiority of glucose-6-phosphate dehydrogenase deficiency diagnosis by a point-of-care rapid test versus the laboratory fluorescent spot test demonstrated by copper inhibition in normal human red blood cells. *Transl Res* 165: 677–688.</jrn>

<jrn>32. Satyagraha AW, Sadhewa A, Elvira R, Elyazar I, Feriandika D, Antonjaya U, Oyong D, Subekti D, Rozi IE, Domingo GJ, Harahap AR, Baird JK, 2016. Assessment of point-of-care diagnostics for G6PD deficiency in malaria endemic rural eastern Indonesia. *PLoS Negl Trop Dis* 10: e0004457.</jrn>

<eref>33. <http://www.who.int/malaria/mpac/mpac-march2015-erg-g6pd.pdf>. Accessed October 20 and 22, 2015.</eref>

<jrn>34. Kuwahata M, Wijesinghe R, Ho MF, Pelecanos A, Bobogare A, Landry L, Bugora H, Vallely A, McCarthy J, 2010. Population screening for glucose-6-phosphate dehydrogenase deficiencies in Isabel Province, Solomon Islands, using a modified enzyme assay on filter paper dried bloodspots. *Malar J* 9: 223.</jrn>

<jrn>35. De Niz M, Eziefula AC, Othieno L, Mbabazi E, Nabukeera D, Ssemmondo E, Gonahasa S, Tumwebaze P, Diliberto D, Maiteki-Sebuguzi C, Staedke SG, Drakeley C, 2013. Tools for mass screening of G6PD deficiency: validation of the WST8/1-methoxy-PMS enzymatic assay in Uganda. *Malar J* 12: 210.</jrn>

<jrn>36. Baird JK, Hoffman SL, 2003. Primaquine for the prevention of malaria in travelers. *Clin Infect Dis* 37: 1659–1667.</jrn>

<jrn>37. Ohrt C, Purnomo, Sutamihardja MA, Tang D, Kain KC, 2002. Impact of microscopy error on estimates of protective efficacy in malaria-prevention trials. *J Infect Dis* 186: 540–546.</jrn>

<jrn>38. Baird JK, Maguire JD, Price RN, 2012. Diagnosis and treatment of *Plasmodium vivax* malaria. *Adv Parasitol* 80: 203–270.</jrn>

<bok>39. World Health Organization, 2010. *Guidelines for the Treatment of Malaria*. 2nd edition. Geneva, Switzerland: WHO.</bok>

<jrn>40. Darlow B, Vrbova H, Gibney S, Jolley D, Stace J, Alpers M, 1982. Sulfadoxine-pyrimethamine for the treatment of acute malaria in children of Papua New Guinea. II. *Plasmodium vivax*. *Am J Trop Med Hyg* 31: 10–13.</jrn>

<jrn>41. Pukrittayakamee S, Chantira A, Simpson JA, Vanijanonta S, Clemens R, Looareesuan S, White NJ, 2000. Therapeutic responses to different antimalarial drugs in vivax malaria. *Antimicrob Agents Chemother* 44: 1680–1685.</jrn>

<jrn>42. Tjitra E, Baker J, Suprianto S, Cheng Q, Anstey NM, 2002. Therapeutic efficacies of artesunate-sulfadoxine-pyrimethamine and chloroquine-sulfadoxine-pyrimethamine in vivax malaria pilot studies: relationship to *Plasmodium vivax dhfr* mutations. *Antimicrob Agents Chemother* 46: 3947–3953.</jrn>

<jrn>43. Maguire JD, Krisin, Marwoto H, Richie TL, Fryauff DJ, Baird JK, 2006. Mefloquine is highly efficacious against chloroquine-resistant *Plasmodium vivax*

- malaria and *Plasmodium falciparum* malaria in Papua, Indonesia. *Clin Infect Dis* 42: 1067–1072.</jrn>
- <jrn>44. Lacy MD, Maguire JD, Barcus MJ, Ling J, Bangs MJ, Gramzinski R, Basri H, Sismadi P, Miller GB, Chulay JD, Fryauff DJ, Hoffman SL, Baird JK, 2002. Atovaquone/proguanil therapy for *Plasmodium falciparum* and *Plasmodium vivax* malaria in Indonesians who lack clinical immunity. *Clin Infect Dis* 35: e92–e95.</jrn>
- <jrn>45. Baird JK, Basri H, Subianto B, Fryauff DJ, McElroy PD, Leksana B, Richie TL, Masbar S, Wignall FS, Hoffman SL, 1995. Treatment of chloroquine-resistant *Plasmodium vivax* with chloroquine and primaquine or halofantrine. *J Infect Dis* 171: 1678–1682.</jrn>
- <jrn>46. Ratcliff A, Siswantoro H, Kenangalem E, Maristela R, Wuwung RM, Laihad F, Ebsworth EP, Anstey NM, Tjitra E, Price RN, 2007. Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison. *Lancet* 369: 757–765.</jrn>
- <jrn>47. Karunajeewa HA, Mueller I, Senn M, Lin E, Law I, Gomorra PS, Oa O, Griffin S, Kotab K, Suano P, Tarongka N, Ura A, Lautu D, Page-Sharp M, Wong R, Salman S, Siba P, Ilett KF, Davis TM, 2008. A trial of combination antimalarial therapies in children from Papua New Guinea. *N Engl J Med* 359: 2545–2557.</jrn>
- <jrn>48. Douglas NM, Anstey NM, Angus BJ, Nosten F, Price RN, 2010. Artemisinin combination therapy for vivax malaria. *Lancet Infect Dis* 10: 405–416.</jrn>
- <jrn>49. Poravuth Y, Socheat D, Rueangweerayut R, Uthaisin C, Pyae Phyo A, Valecha N, Rao BH, Tjitra E, Purnama A, Borghini-Fuhrer I, Duparc S, Shin CS, Fleckenstein L, 2011. Pyronaridine-artesunate versus chloroquine in patients with acute *Plasmodium vivax* malaria: a randomized, double-blind, non-inferiority trial. *PLoS One* 6: e14501.</jrn>
- <jrn>50. Gogtay N, Kannan S, Thatte UM, Olliaro PL, Sinclair D, 2013. Artemisinin-based combination therapy for treating uncomplicated *Plasmodium vivax* malaria. *Cochrane Database Syst Rev* 10: CD008492.</jrn>
- <bok>51. World Health Organization, 2012. *World Malaria Report 2012*. Geneva, Switzerland: WHO.</bok>
- <jrn>52. Barcus MJ, Basri H, Picarima H, Manyakori C, Sekartuti, Elyazar I, Bangs MJ, Maguire JD, Baird JK, 2007. Demographic risk factors for severe and fatal vivax and falciparum malaria among hospital admissions in northeastern Indonesian Papua. *Am J Trop Med Hyg* 77: 984–991.</jrn>
- <jrn>53. Tjitra E, Anstey NM, Sugiarto P, Warikar N, Kenangalem E, Karyana M, Lampah DA, Price RN, 2008. Multidrug-resistant *Plasmodium vivax* associated with severe and fatal malaria: a prospective study in Papua, Indonesia. *PLoS Med* 5: e128.</jrn>
- <jrn>54. Genton B, D’Acremont V, Rare L, Baea K, Reeder JC, Alpers MP, Muller I, 2008. *Plasmodium vivax* and mixed infections are associated with severe malaria in children: a prospective cohort study from Papua New Guinea. *PLoS Med* 5: e127.</jrn>

- <jrn>55. Kochar DK, Das A, Kochar SK, Saxena V, Sirohi P, Garg S, Kochar A, Khatri MP, Gupta V, 2009. Severe *Plasmodium vivax* malaria: a report on serial cases from Bikaner in northwestern India. *Am J Trop Med Hyg* 80: 194–198.</jrn>
- <jrn>56. Alexandre MA, Ferreira CO, Siqueira AM, Magalhaes BL, Mourao MP, Lacerda MV, Alecrim MD, 2010. Severe *Plasmodium vivax* malaria, Brazilian Amazon. *Emerg Infect Dis* 16: 1611–1614.</jrn>
- <jrn>57. Andrade BB, Reis-Filho A, Souza-Neto SM, Clarencio J, Camargo LM, Barral A, Barral-Netto M, 2010. Severe *Plasmodium vivax* malaria exhibits marked inflammatory imbalance. *Malar J* 9: 13.</jrn>
- <jrn>58. Price L, Planche T, Rayner C, Krishna S, 2007. Acute respiratory distress syndrome in *Plasmodium vivax* malaria: case report and review of the literature. *Trans R Soc Trop Med Hyg* 101: 655–659.</jrn>
- <jrn>59. Anstey NM, Russell B, Yeo TW, Price RN, 2009. The pathophysiology of vivax malaria. *Trends Parasitol* 25: 220–227.</jrn>
- <jrn>60. Tan LK, Yacoub S, Scott S, Bhagani S, Jacobs M, 2008. Acute lung injury and other serious complications of *Plasmodium vivax* malaria. *Lancet Infect Dis* 8: 449–454.</jrn>
- <jrn>61. Lampah DA, Yeo TW, Hardianto SO, Tjitra E, Kenangalem E, Sugiarto P, Price RN, Anstey NM, 2011. Coma associated with microscopy-diagnosed *Plasmodium vivax*: a prospective study in Papua, Indonesia. *PLoS Negl Trop Dis* 5: e1032.</jrn>
- <jrn>62. Anstey NM, Douglas NM, Poespoprodjo JR, Price RN, 2012. *Plasmodium vivax*: clinical spectrum, risk factors and pathogenesis. *Adv Parasitol* 80: 151–201.</jrn>
- <jrn>63. Dondorp A, Nosten F, Stepniewska K, Day N, White N; South East Asian Quinine Artesunate Malaria Trial (SEAQUAMAT) Group, 2005. Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. *Lancet* 366: 717–725.</jrn>
- <jrn>64. Dondorp AM, Fanello CI, Hendriksen IC, Gomes E, Seni A, Chhaganlal KD, Bojang K, Olaosebikan R, Anunobi N, Maitland K, Kivaya E, Agbenyega T, Nguah SB, Evans J, Gesase S, Kahabuka C, Mtove G, Nadjm B, Deen J, Mwanga-Amumpaire J, Nansumba M, Karema C, Umulisa N, Uwimana A, Mokuolu OA, Adedoyin OT, Johnson WB, Tshefu AK, Onyamboko MA, Sakulthaew T, Ngum WP, Silamut K, Stepniewska K, Woodrow CJ, Bethell D, Wills B, Oneko M, Peto TE, von Seidlein L, Day NP, White NJ; AQUAMAT group, 2010. Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. *Lancet* 376: 1647–1657.</jrn>
- <jrn>65. Rieckmann KH, Davis DR, Hutton DC, 1989. *Plasmodium vivax* resistance to chloroquine? *Lancet* 2: 1183–1184.</jrn>
- <jrn>66. Baird JK, Basri H, Purnomo, Bangs MJ, Subianto B, Patchen LC, Hoffman SL, 1991. Resistance to chloroquine by *Plasmodium vivax* in Irian Jaya, Indonesia. *Am J Trop Med Hyg* 44: 547–552.</jrn>

- <jrn>67. Price RN, Auburn S, Marfurt J, Cheng Q, 2012. Phenotypic and genotypic characterization of drug-resistant *Plasmodium vivax*. *Trends Parasitol* 28: 522–529.</jrn>
- <jrn>68. Sumawinata IW, Bernadeta, Leksana B, Sutamihardja A, Purnomo, Subianto B, Sekartuti, Fryauff DJ, Baird JK, 2003. Very high risk of therapeutic failure with chloroquine for uncomplicated *Plasmodium falciparum* and *P. vivax* malaria in Indonesian Papua. *Am J Trop Med Hyg* 68: 416–420.</jrn>
- <jrn>69. Ratcliff A, Siswantoro H, Kenangalem E, Wuwung M, Brockman A, Edstein MD, Laihad F, Ebsworth EP, Anstey NM, Tjitra E, Price RN, 2007. Therapeutic response of multidrug-resistant *Plasmodium falciparum* and *P. vivax* to chloroquine and sulfadoxine-pyrimethamine in southern Papua, Indonesia. *Trans R Soc Trop Med Hyg* 101: 351–359.</jrn>
- <jrn>70. Baird JK, 2004. Chloroquine resistance in *Plasmodium vivax*. *Antimicrob Agents Chemother* 48: 4075–4083.</jrn>
- <jrn>71. Price RN, Douglas NM, Anstey NM, 2009. New developments in *Plasmodium vivax* malaria: severe disease and the rise of chloroquine resistance. *Curr Opin Infect Dis* 22: 430–435.</jrn>
- <jrn>72. Price RN, von Seidlein L, Valecha N, Nosten F, Baird JK, White NJ, 2014. Global extent of chloroquine-resistant *Plasmodium vivax*: a systematic review and meta-analysis. *Lancet Infect Dis* 10: 982–991.</jrn>
- <jrn>73. Imwong M, Pukrittayakamee S, Gruner AC, Renia L, Letourneur F, Looareesuwan S, White NJ, Snounou G, 2005. Practical PCR genotyping protocols for *Plasmodium vivax* using *Pvcs* and *Pvmsp1*. *Malar J* 4: 20.</jrn>
- <jrn>74. Chen N, Auliff A, Rieckmann K, Gatton M, Cheng Q, 2007. Relapses of *Plasmodium vivax* infection result from clonal hypnozoites activated at predetermined intervals. *J Infect Dis* 195: 934–941.</jrn>
- <jrn>75. Koepfli C, Mueller I, Marfurt J, Goroti M, Sie A, Oa O, Genton B, Beck HP, Felger I, 2009. Evaluation of *Plasmodium vivax* genotyping markers for molecular monitoring in clinical trials. *J Infect Dis* 199: 1074–1080.</jrn>
- <jrn>76. Barnadas C, Koepfli C, Karunajeewa HA, Siba PM, Davis TM, Mueller I, 2011. Characterization of treatment failure in efficacy trials of drugs against *Plasmodium vivax* by genotyping neutral and drug resistance-associated markers. *Antimicrob Agents Chemother* 55: 4479–4481.</jrn>
- <jrn>77. Imwong M, Snounou G, Pukrittayakamee S, Tanomsing N, Kim JR, Nandy A, Guthmann JP, Nosten F, Carlton J, Looareesuwan S, Nair S, Sudimack D, Day NP, Anderson TJ, White NJ, 2007. Relapses of *Plasmodium vivax* infection usually result from activation of heterologous hypnozoites. *J Infect Dis* 195: 927–933.</jrn>
- <jrn>78. White NJ, 2011. Determinants of relapse periodicity in *Plasmodium vivax* malaria. *Malar J* 10: 297.</jrn>

- <jrn>79. Udomsangpetch R, Somsri S, Panichakul T, Chotivanich K, Sirichaisinthop J, Yang Z, Cui L, Sattabongkot J, 2007. Short-term in vitro culture of field isolates of *Plasmodium vivax* using umbilical cord blood. *Parasitol Int* 56: 65–69.</jrn>
- <jrn>80. Golenda CF, Li J, Rosenberg R, 1997. Continuous in vitro propagation of the malaria parasite *Plasmodium vivax*. *Proc Natl Acad Sci USA* 94: 6786–6791.</jrn>
- <jrn>81. Tasanor O, Ruengweerayut R, Sirichaisinthop J, Congpuong K, Wernsdorfer WH, Na-Bangchang K, 2006. Clinical-parasitological response and in-vitro sensitivity of *Plasmodium vivax* to chloroquine and quinine on the western border of Thailand. *Trans R Soc Trop Med Hyg* 100: 410–418.</jrn>
- <jrn>82. Russell BM, Udomsangpetch R, Rieckmann KH, Kotecka BM, Coleman RE, Sattabongkot J, 2003. Simple in vitro assay for determining the sensitivity of *Plasmodium vivax* isolates from fresh human blood to antimalarials in areas where *P. vivax* is endemic. *Antimicrob Agents Chemother* 47: 170–173.</jrn>
- <jrn>83. Chotivanich K, Udomsangpetch R, Chierakul W, Newton PN, Ruangveerayuth R, Pukrittayakamee S, Looareesuwan S, White NJ, 2004. In vitro efficacy of antimalarial drugs against *Plasmodium vivax* on the western border of Thailand. *Am J Trop Med Hyg* 70: 395–397.</jrn>
- <jrn>84. Suwanarusk R, Russell B, Chavchich M, Chalfein F, Kenangalem E, Kosaisavee V, Prasetyorini B, Piera KA, Barends M, Brockman A, Let-Uthai U, Anstey NM, Titra E, Nosten F, Cheng Q, Price RN, 2007. Chloroquine resistant *Plasmodium vivax*: in vitro characterisation and association with molecular polymorphisms. *PLoS One* 2: e1089.</jrn>
- <jrn>85. Hasugian AR, Tjitra E, Ratcliff A, Siswantoro H, Kenangalem E, Wuwung RM, Purba HL, Piera KA, Chalfien F, Marfurt J, Penttinen PM, Russell B, Anstey NM, Price RN, 2009. In vivo and in vitro efficacy of amodiaquine monotherapy for treatment of infection by chloroquine-resistant *Plasmodium vivax*. *Antimicrob Agents Chemother* 53: 1094–1099.</jrn>
- <jrn>86. Suwanarusk R, Chavchich M, Russell B, Jaidee A, Chalfein F, Barends M, Prasetyorini B, Kenangalem E, Piera KA, Lek-Uthai U, Anstey NM, Titra E, Nosten F, Cheng Q, Price RN, 2008. Amplification of *pvmdr1* associated with multidrug-resistant *Plasmodium vivax*. *J Infect Dis* 198: 1558–1564.</jrn>
- <jrn>87. Chotivanich K, Sattabongkot J, Choi YK, Park JS, Sritabal J, Lim CS, Udomsangpetch R, White NJ, Lee WJ, 2009. Antimalarial drug susceptibility of *Plasmodium vivax* in the Republic of Korea. *Am J Trop Med Hyg* 80: 902–904.</jrn>
- <jrn>88. Lek-Uthai U, Suwanarusk R, Ruengweerayut R, Skinner-Adams TS, Nosten F, Gardiner DL, Boonma P, Piera KA, Andrews KT, Machunter B, McCarthy JS, Anstey NM, Price RN, Russell B, 2008. Stronger activity of human immunodeficiency virus type 1 protease inhibitors against clinical isolates of *Plasmodium vivax* than against those of *P. falciparum*. *Antimicrob Agents Chemother* 52: 2435–2441.</jrn>
- <jrn>89. Marfurt J, Chalfein F, Prayoga P, Wabiser F, Kenangalem E, Piera KA, Fairlie DP, Tjitra E, Anstey NM, Andrews KT, Price RN, 2011. Ex vivo activity of histone

- deacetylase inhibitors against multidrug-resistant clinical isolates of *Plasmodium falciparum* and *P. vivax*. *Antimicrob Agents Chemother* 55: 961–966.</jrn>
- <jrn>90. Marfurt J, Chalfein F, Prayoga P, Wabiser F, Kenangalem E, Piera KA, Machunter B, Tjitra E, Anstey NM, Price RN, 2011. Ex vivo drug susceptibility of ferroquine against chloroquine-resistant isolates of *Plasmodium falciparum* and *P. vivax*. *Antimicrob Agents Chemother* 55: 4461–4464.</jrn>
- <jrn>91. Price RN, Marfurt J, Chalfein F, Kenangalem E, Piera KA, Tjitra E, Anstey NM, Russell B, 2010. In vitro activity of pyronaridine against multidrug-resistant *Plasmodium falciparum* and *Plasmodium vivax*. *Antimicrob Agents Chemother* 54: 5146–5150.</jrn>
- <jrn>92. Marfurt J, Chalfein F, Prayoga P, Wabiser F, Wirjanata G, Sebayang B, Piera KA, Wittlin S, Haynes RK, Mohrle JJ, Anstey NM, Kenangalem E, Price RN, 2012. Artemisinin-based combination therapy against *P. vivax*: comparative ex vivo activity of next-generation endoperoxides in multidrug resistant field isolates. *Antimicrob Agents Chemother* 56: 5258–5263.</jrn>
- <jrn>93. Druilhe P, Brasseur P, Blanc C, Makler M, 2007. Improved assessment of *Plasmodium vivax* response to antimalarial drugs by a colorimetric double-site *Plasmodium* lactate dehydrogenase antigen capture enzyme-linked immunosorbent assay. *Antimicrob Agents Chemother* 51: 2112–2116.</jrn>
- <jrn>94. Nomura T, Carlton JM, Baird JK, del Portillo HA, Fryauff DJ, Rathore D, Fidock DA, Su X, Collins WE, McCutchan TF, Wootton JC, Wellems TE, 2001. Evidence for different mechanisms of chloroquine resistance in 2 *Plasmodium* species that cause human malaria. *J Infect Dis* 183: 1653–1661.</jrn>
- <jrn>95. Barnadas C, Ratsimbaoa A, Tichit M, Bouchier C, Jahevitra M, Picot S, Menard D, 2008. *Plasmodium vivax* resistance to chloroquine in Madagascar: clinical efficacy and polymorphisms in *pvmdr1* and *pvcrt-o* genes. *Antimicrob Agents Chemother* 52: 4233–4240.</jrn>
- <jrn>96. Fernandez-Becerra C, Pinazo MJ, Gonzalez A, Alonso PL, del Portillo HA, Gascon J, 2009. Increased expression levels of the *pvcrt-o* and *pvmdr1* genes in a patient with severe *Plasmodium vivax* malaria. *Malar J* 8: 55.</jrn>
- <jrn>97. Marfurt J, de Monbrison F, Brega S, Barbolat L, Muller I, Sie A, Goroti M, Reeder JC, Beck HP, Picot S, Genton B, 2008. Molecular markers of in vivo *Plasmodium vivax* resistance to amodiaquine plus sulfadoxine-pyrimethamine: mutations in *pvdhfr* and *pvmdr1*. *J Infect Dis* 198: 409–417.</jrn>
- <jrn>98. Sa JM, Nomura T, Neves J, Baird JK, Wellems TE, del Portillo HA, 2005. *Plasmodium vivax*: allele variants of the *mdr1* gene do not associate with chloroquine resistance among isolates from Brazil, Papua, and monkey-adapted strains. *Exp Parasitol* 109: 256–259.</jrn>
- <jrn>99. Kim YK, Kim C, Park I, Kim HY, Choi JY, Kim JM, 2011. Therapeutic efficacy of chloroquine in *Plasmodium vivax* and the *pvmdr1* polymorphisms in the Republic of Korea under mass chemoprophylaxis. *Am J Trop Med Hyg* 84: 532–534.</jrn>

- <jrn>100. Dern RJ, Weinstein IM, Leroy GV, Talmage DW, Alving AS, 1954. The hemolytic effect of primaquine. I. The localization of the drug-induced hemolytic defect in primaquine-sensitive individuals. *J Lab Clin Med* 43: 303–309.</jrn>
- <jrn>101. Beutler E, 1959. The hemolytic effect of primaquine and related compounds: a review. *Blood* 14: 103–139.</jrn>
- <jrn>102. Clyde DF, McCarthy VC, 1977. Radical cure of Chesson strain vivax malaria in man by 7, not 14, days of treatment with primaquine. *Am J Trop Med Hyg* 26: 562–563.</jrn>
- <jrn>103. Hill DR, Baird JK, Parise ME, Lewis LS, Ryan ET, Magill AJ, 2006. Primaquine: report from CDC expert meeting in malaria chemoprophylaxis I. *Am J Trop Med Hyg* 75: 402–415.</jrn>
- <jrn>104. John GK, Douglas NM, von Seidlein L, Nosten F, Baird JK, White NJ, Price RN, 2012. Primaquine radical cure of *Plasmodium vivax*: a critical review of the literature. *Malar J* 11: 280.</jrn>
- <jrn>105. Baird JK, 2009. Resistance to therapies for infection by *Plasmodium vivax*. *Clin Microbiol Rev* 22: 508–534.</jrn>
- <jrn>106. Galappaththy GN, Omari AA, Tharyan P, 2007. Primaquine for preventing relapses in people with *Plasmodium vivax* malaria. *Cochrane Database Syst Rev* CD004389.</jrn>
- <jrn>107. Sutanto I, Tjahjono B, Basri H, Taylor WR, Putri FA, Meilia RA, Setiabudy R, Nurleila S, Ekawati LL, Elyazar I, Farrar J, Sudoyo H, Baird JK, 2013. Randomized, open-label trial of primaquine against vivax malaria relapse in Indonesia. *Antimicrob Agents Chemother* 57: 1128–1135.</jrn>
- <jrn>108. Nelwan EJ, Ekawati LL, Tjahono B, Setiabudy R, Sutanto I, Chand K, Ekasari T, Djoko D, Basri H, Taylor WR, Duparc S, Subekti D, Elyazar I, Noviyanti R, Sudoyo H, Baird JK, 2015. Randomized trial of primaquine hypnozoitocidal efficacy when administered with artemisinin-combined blood schizontocides for radical cure of *Plasmodium vivax* in Indonesia. *BMC Med* 13: 294.</jrn>
- <jrn>109. Takeuchi R, Lawpoolsri S, Imwong M, Kobayashi J, Kaewkungwal J, Pukrittayakamee S, Puangsa-art S, Thanyavanich N, Maneeboonyang W, Day NP, Singhasivanon P, 2010. Directly-observed therapy (DOT) for the radical 14-day primaquine treatment of *Plasmodium vivax* malaria on the Thai-Myanmar border. *Malar J* 9: 308.</jrn>
- <jrn>110. Maneeboonyang WLS, Puangsa-Art S, Yimsamran S, Thanyavanich N, Wuthisen P, Prommongkol S, Chaimongkul W, Rukmanee P, Rukmanee N, Chavez IF, Buchachart K, Krudsood S, Singhasivanon P, 2011. Directly observed therapy with primaquine to reduce the recurrence rate of *Plasmodium vivax* infection along the Thai-Myanmar border. *Southeast Asian J Trop Med Public Health* 42: 9–18.</jrn>
- <jrn>111. Leslie T, Rab MA, Ahmadzai H, Durrani N, Fayaz M, Kolaczinski J, Rowland M, 2004. Compliance with 14-day primaquine therapy for radical cure of vivax malaria—a randomized placebo-controlled trial comparing unsupervised with supervised treatment. *Trans R Soc Trop Med Hyg* 98: 168–173.</jrn>

- <jrn>112. Krudsood S, Tangpukdee N, Wilairatana P, Phophak N, Baird JK, Brittenham GM, Looareesuwan S, 2008. High-dose primaquine regimens against relapse of *Plasmodium vivax* malaria. *Am J Trop Med Hyg* 78: 736–740.</jrn>
- <jrn>113. Ingram RJ, Crenna-Darusallam C, Soebianto S, Noviyanti R, Baird JK, 2014. The clinical and public health problem of relapse despite primaquine therapy: case review of repeated relapses of *Plasmodium vivax* acquired in Papua New Guinea. *Malar J* 13: 488.</jrn>
- <jrn>114. Bennett JW, Pybus BS, Yadava A, Tosh D, Sousa JC, McCarthy WF, Deye G, Melendez V, Ockenhouse CF, 2013. Primaquine failure and cytochrome P-450 2D6 in *Plasmodium vivax* malaria. *N Engl J Med* 369: 1381–1382.</jrn>
- <bok>115. Recht R, Ashley E, White N, 2014. *Safety of 8-Aminoquinoline Antimalarial Medicines*. Geneva, Switzerland: World Health Organization.</bok>
- <jrn>116. Lacerda MV, Fragoso SC, Alecrim MG, Alexandre MA, Magalhaes BM, Siqueira AM, Ferreira LC, Araujo JR, Mourao MP, Ferrer M, Castillo P, Martin-Jaular L, Fernandez-Becerra C, del Portillo H, Ordi J, Alonso PL, Bassat Q, 2012. Postmortem characterization of patients with clinical diagnosis of *Plasmodium vivax*: to what extent does this parasite kill? *Clin Infect Dis* 55: e67–e74.</jrn>
- <jrn>117. Monteiro WM, Moura-Neto JP, Recht J, Bassat Q, Lacerda MV, 2016. Fatal primaquine-induced hemolysis in a patient with *Plasmodium vivax* malaria and G6PD A(–) variant in the Brazilian Amazon. *Clin Infect Dis* 62: 1188.</jrn>
- <jrn>118. Grietens KPSV, Erhart A, Ribera JM, Toomer E, Tenorio A, Montalvo TG, Rodriguez H, Cuentas AL, D'Alessandro U, Gamboa D, 2010. Adherence to 7-day primaquine treatment for the radical cure of *P. vivax* in the Peruvian Amazon. *Am J Trop Med Hyg* 82: 1017–1023.</jrn>
- <jrn>119. Alving AS, Johnson CF, Tarlov AR, Brewer GJ, Kellermeyer RW, Carson PE, 1960. Mitigation of the haemolytic effect of primaquine and enhancement of its action against exoerythrocytic forms of the Chesson strain of *Plasmodium vivax* by intermittent regimens of drug administration. A preliminary report. *Bull World Health Organ* 22: 621–631.</jrn>
- <jrn>120. Burgess RW, Bray RS, 1961. The effect of a single dose of primaquine on the gametocytes and sporogony of *Laverania* (= *Plasmodium*) *falciparum*. *Bull World Health Organ* 24: 451–456.</jrn>
- <jrn>121. Rieckmann KH, McNamara JV, Kass L, Powell RD, 1969. Gametocytocidal and sporontocidal effects of primaquine upon two strains of *Plasmodium falciparum*. *Mil Med* 134: 802–819.</jrn>
- <jrn>122. Clyde DF, 1981. Clinical problems associated with the use of primaquine as a tissue schizontocidal and gametocytocidal drug. *Bull World Health Organ* 59: 128–134.</jrn>
- <jrn>123. Baird JK, Surjadjaja C, 2011. Consideration of ethics in primaquine therapy against malaria transmission. *Trends Parasitol* 27: 11–16.</jrn>

- <jrn>124. Kheng S, Muth S, Taylor WR, Tops N, Kosal K, Sothea K, Souy P, Kim S, Char CM, Vanna C, Ly P, Ringwald P, Khieu V, Kerleguer A, Tor P, Baird JK, Bjorge S, Menard D, Christophel E, 2015. Tolerability and safety of weekly primaquine against relapse of *Plasmodium vivax* in Cambodians with G6PD deficiency. *BMC Med* 13: 203.</jrn>
- <jrn>125. Wang J, Xiao QZ, Chen YM, Yi S, Liu D, Liu YH, Zhang CM, Wei XF, Zhou YQ, Zhong XM, Zhao CY, Xiong F, Wei XC, Xu XM, 2014. DNA hypermethylation and X chromosome inactivation are major determinants of phenotypic variation in women heterozygous for G6PD mutations. *Blood Cells Mol Dis* 53: 241–245.</jrn>
- <jrn>126. Baird JK, 2011. Resistance to chloroquine unhinges vivax malaria therapeutics. *Antimicrob Agents Chemother* 55: 1827–1830.</jrn>
- <jrn>127. Douglas NM, Nosten F, Ashley EA, Phaiphun L, van Vugt M, Singhasivanon P, White NJ, Price RN, 2011. *Plasmodium vivax* recurrence following falciparum and mixed species malaria: risk factors and effect of antimalarial kinetics. *Clin Infect Dis* 52: 612–620.</jrn>
- <jrn>128. Baird JK, 2011. Radical cure: the case for anti-relapse therapy against all the malarias. *Clin Infect Dis* 52: 621–623.</jrn>
- <jrn>129. White NJ, Pukrittayakamee S, Phyo AP, Rueangweerayut R, Nosten F, Jittamala P, Jeeyapant A, Jain JP, Lefevre G, Li R, Magnusson B, Diagana TT, Leong FJ, 2014. Spiroindolone KAE609 for falciparum and vivax malaria. *N Engl J Med* 371: 403–410.</jrn>
- <jrn>130. Nilsen A, LaCrue AN, White KL, Forquer IP, Cross RM, Marfurt J, Mather MW, Delves MJ, Shackleford DM, Saenz FE, Morrissey JM, Steuten J, Mutka T, Li Y, Wirjanata G, Ryan E, Duffy S, Kelly JX, Sebayang BF, Zeeman AM, Noviyanti R, Sinden RE, Kocken CH, Price RN, Avery VM, Angulo-Barturen I, Jimenez-Diaz MB, Ferrer S, Herreros E, Sanz LM, Gamo FJ, Bathurst I, Burrows JN, Siegl P, Guy RK, Winter RW, Vaidya AB, Charman SA, Kyle DE, Manetsch R, Riscoe MK, 2013. Quinolone-3-diarylethers: a new class of antimalarial drug. *Sci Transl Med* 5: 177ra37.</jrn>
- <jrn>131. Wells TN, Burrows JN, Baird JK, 2010. Targeting the hypnozoite reservoir of *Plasmodium vivax*: the hidden obstacle to malaria elimination. *Trends Parasitol* 26: 145–151.</jrn>
- <jrn>132. Llanos-Cuentas A, Lacerda MV, Rueangweerayut R, Krudsood S, Gupta SK, Kochar SK, Arthur P, Cheunhom N, Mohrle JJ, Duparc S, Ugwuegbulam C, Kleim JP, Carter N, Green JA, Kellam L, 2014. Tafenoquine plus chloroquine for the treatment and relapse prevention of *Plasmodium vivax* malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study. *Lancet* 383: 1049–1058.</jrn>
- <jrn>133. Baird JK, 2012. Reinventing primaquine for endemic malaria. *Expert Opin Emerg Drugs* 17: 439–444.</jrn>
- <jrn>134. Müller O, Mockenhaupt FP, Marks B, Meissner P, Coulibaly B, Kuhnert R, Buchner H, Schirmer RH, Walter-Sack I, Sie A, Mansmann U, 2013. Haemolysis risk in methylene blue treatment of G6PD-sufficient and G6PD-deficient West-African children

with uncomplicated falciparum malaria: a synopsis of four RCTs. *Pharmacoepidemiol Drug Saf* 22: 376–385.</jrn>

- <jrn>135. Adak T, Valecha N, Sharma VP, 2001. *Plasmodium vivax* polymorphism in a clinical drug trial. *Clin Diagn Lab Immunol* 8: 891–894.</jrn>
- <jrn>136. Valecha N, Adak T, Bagga AK, Asthana OP, Srivastava JS, Joshi H, Sharma VP, 2001. Comparative antirelapse efficacy of bulaquine and primaquine in double blind clinical trial. *Curr Sci* 80: 561–563.</jrn>
- <jrn>137. Krudsood S, Wilairatana P, Tangpukdee N, Chalermrut K, Srivilairit S, Thanachartwet V, Muangnoicharoen S, Luplertlop N, Brittenham GM, Looareesuwan S, 2006. Safety and tolerability elubaquine (bulaquine, CDRI 80/53) for treatment of *Plasmodium vivax* malaria in Thailand. *Korean J Parasitol* 44: 221–228.</jrn>
- <jrn>138. Macareo L, Lwin KM, Cheah PY, Yuentrakul P, Miller RS, Nosten F, 2013. Triangular test design to evaluate tinidazole in the prevention of *Plasmodium vivax* relapse. *Malar J* 12: 173.</jrn>
- <jrn>139. Meister S, Plouffe DM, Kuhen KL, Bonamy GMC, Wu T, Barnes SW, Bopp SE, Borboa R, Bright AT, Che J, Cohen S, Dharia NV, Gagaring K, Gettayacamin M, Gordon P, Groessl T, Kato N, Lee MCS, McNamara CW, Fidock DA, Nagle A, Nam T, Richmond W, Roland J, Rottman M, Zhou B, Froissard P, Glynne RJ, Mazier D, Sattabongkot J, Schultz PG, Tuntland T, Walker JR, Zhou Y, Chatterjee A, Diagana TT, Winzeler EA, 2011. Imaging of *Plasmodium* liver stages to drive next-generation antimalarial drug discovery. *Science* 334: 1372–1377.</jrn>
- <jrn>140. Dembele L, Gego A, Zeeman AM, Fraetich JF, Silvie O, Rametti A, Le Grand R, Dereuddre-Bosquet N, Sauerwein R, van Gemert GJ, Vaillant JC, Thomas AW, Snounou G, Kocken CHM, Mazier D, 2011. Towards an in vitro model of *Plasmodium* hypnozoites suitable for drug discovery. *PLoS One* 6: e18162.</jrn>
- <jrn>141. Dembele L, Franetich JF, Lorthiois A, Gego A, Zeeman AM, Kocken CH, Le Grand R, Dereuddre-Bosquet N, van Gemert GJ, Sauerwein R, Vaillant JC, Hannoun L, Fuchter MJ, Diagana TT, Malmquist NA, Scherf A, Snounou G, Mazier D, 2014. Persistence and activation of malaria hypnozoites in long-term primary hepatocyte cultures. *Nat Med* 20: 307–312.</jrn>
- <jrn>142. Delves M, Plouffe D, Scheurer C, Meister S, Wittlin S, Winzeler EA, Sinden RE, Leroy D, 2012. The activities of current antimalarial drugs on the life cycle stages of *Plasmodium*: a comparative study with human and rodent parasites. *PLoS Med* 9: e1001169.</jrn>

FIGURE 1. Clinical reports of chloroquine-resistant *Plasmodium vivax*. Red icons highlight areas of chloroquine-resistant parasites defined by greater than 10% recurrence (and lower 95% confidence interval [CI] >5%) by day 28 with or without measurement of chloroquine drug concentration; dark orange diamonds locate area suggestive of resistance as defined by 5–10% recurrence by day 28, confirmed with adequate chloroquine drug concentrations; light orange icons locate sites of possible resistance as defined by less than 5–10% recurrence by day 28 but with lower 95% CI <5% by day 28, without drug concentrations. Yellow icons represent case reports. Details of clinical trials are provided in Supplemental Annex A.

FIGURE 2. Clinical reports of chloroquine-sensitive (CQS) *Plasmodium vivax*. CQS was defined as < 5% recurrence by day 28, no early administration of primaquine, and all patients from symptomatic clinical

presentation. Yellow icons represent studies before 2007, orange icons studies between 2007 and 2012. Details of clinical trials are provided in Supplemental Annex A.

FIGURE 3. Risk of recurrence at the end of the study following very low-dose primaquine (PQ) (total dose ≤ 2.5 mg/kg), low-dose PQ (total dose > 2.5 mg/kg to < 5.0 mg/kg), high-dose PQ (total dose > 5.0 mg/kg). Indonesia and Papua New Guinea [closed circles]; Thailand and Vietnam (open circles); South and Central America (open squares); Indian subcontinent, Middle East, and Horn of Africa (open diamonds); and Korea and China (closed diamonds). The U.S. studies of induced malaria and returning soldiers are categorized according to origin of infecting strain.

FIGURE 4. Forest plot of the effectiveness of low-dose primaquine in studies with a control arm. * Indian subcontinent, ^ United States (Korea), ^^ United States (Chesson), # Thailand, ## Indonesia, + Ethiopia. This figure appears in color at www.ajtmh.org.

FIGURE 5. Forest plot of the effectiveness of high-dose primaquine in studies with a control arm. * Indian subcontinent, ^ United States (Korea), ^^ United States (Chesson), # Thailand, ## Indonesia, + Ethiopia. This figure appears in color at www.ajtmh.org.

FIGURE 6. National malaria treatment guidelines and recommendations concerning primaquine anti-relapse therapy and G6PD screening, reprinted with permission of World Health Organization.

TABLE 1

Top scoring rapid diagnostic test brands for diagnosis of acute vivax malaria*

Brand	Manufacturer	Product catalog no.
CareStart kits (5)	AccessBio, Inc.	G0111, G0121, G0131, G0161, G0171
SD Bioline kits (4)	Standard Diagnostics, Inc.	05FK60, 05FK66, 05FK80, 05FK100
BIONOTE Malaria P.f. and P.v. Ag Rapid Test Kit	Bionote, Inc.	RG19-12
Humasis Malaria P.f/P.v Antigen Test	Humasis Co. Ltd.	AMFV-7025
NanoSign Malaria PF/Pan Ag 3.0	Bioland Ltd.	RMAP-10

* Parasite detection score $> 90\%$, false positive rate $< 10\%$, error rate $< 10\%$ for both *Plasmodium falciparum* and *Plasmodium vivax* at 200 parasites/ μL in Round 4 of the World Health Organization evaluation of these devices.¹⁰

TABLE 2

G6PDd validated quantitative assays and the commercial providers

Kit name	Manufacturer	Venipuncture	Test readout	Chemical basis	Cold storage
G6PD deficiency	Trinity Biotech, Ireland	Yes	Quantitative	Spectrophotometric	Yes
G-Six Kinetic	Tulip Group, India	Yes	Quantitative	Spectrophotometric	Yes
R&D G6PD quantitative	N. Dimopoulos S.A., Greece	Optional	Quantitative	Spectrophotometric	Yes
R&D G6PD qualitative	N. Dimopoulos S.A., Greece	Optional	Qualitative	Ultra-violet fluorescence	Yes
G6PD-WST	Dojindo, Japan	Optional	Qualitative	Dye reduction	Yes
G-SIX	Tulip Group, India	Yes	Qualitative	Met-Hb reduction	No
G6PD deficiency	Trinity Biotech, Ireland	Yes	Qualitative	Ultra-violet	Yes

G6PD deficiency	Trinity Biotech, Ireland	Yes	Qualitative	fluorescence	
MBK	Span, India	Yes	Qualitative	Dye reduction	Yes
BinaxNOW G6PD	Alere/Inverness Medical, United States	Yes	Qualitative	Dye reduction	No
CareStart G6PD	AccessBio, United States	No	Qualitative	Dye reduction	No

TABLE 3

Common sources for misdiagnosis of CQR and CQS *Plasmodium vivax*

	Explanation	Recommendation
Incorrect diagnosis of CQS		
Enrollment of patients without clinical disease	Host immunity in asymptomatic patients enrolled from cross-sectional surveys, may facilitate clearance of parasitaemia even following partially effective drug treatment	Restrict efficacy trials to patients presenting with clinical disease
Coadministration of early PQ	Early PQ has schizontocidal activity that can increase parasite clearance and prevent recrudescence infections	Primaquine treatment should be delayed until the end of the follow-up period
Short duration of follow-up	Early evidence of resistance is manifest by late recrudescence	Patients should be followed up for a minimum of 28 days
Incorrect diagnosis of CQR		
Incomplete treatment course	From poor patient adherence	Supervision of drug treatment
Dose of chloroquine administered too low	Prescription of inadequate mg/kg dose	Documentation of exact dose of drug administered
Poor absorption of drug	Either from poor quality drug, reduced gastrointestinal absorption	Measurement of drug blood concentrations on day 7 and the day of parasite recurrence
Poor drug quality	Faulty product	Confirmation of adequate drug levels, pharmacologic evaluation of study drugs, and purchase only from certified, trusted producers
Inadequate sample size	Leading to wide confidence intervals of high failure rates derived from very few cases	Recruitment of an adequate sample (> 70 patients)

CQR = chloroquine resistant; CQS = chloroquine sensitive; PQ = primaquine.

SUPPLEMENTAL ANNEX A

Trials of antimalarials against erythrocytic stages of *Plasmodium vivax* infection from 1980 to 2013 (supplemental to Price and others⁷²)

First author	Year	Title	Journal	Volume	Issue	Page	PubMed ID
Abdallah	2012	Efficacy of artemether-lumefantrine as a treatment of uncomplicated <i>Plasmodium vivax</i> malaria in eastern Sudan	<i>Malaria J</i>	11	1	404	23217037
Adak	2001	<i>Plasmodium vivax</i> polymorphism in a clinical drug trial	<i>Clin Diagn Laboratory</i>	8	5	891–894	11527798

Alcantara	1985	A comparative clinical study of mefloquine and chloroquine in the treatment of vivax malaria	<i>ry Immunol Southeast Asian J Trop Med Public Health</i>	16	4	535–539	3915155
Anez	2012	Therapeutic response of <i>Plasmodium vivax</i> to chloroquine in Bolivia [in Spanish]	<i>Biomedica</i>	32	4	527–535	23715228
Awab	2010	Dihydroartemisinin-piperaquine vs. chloroquine to treat vivax malaria in Afghanistan: an open randomized, non-inferiority, trial	<i>Malaria J</i>	9	1	105	20409302
Baird	1995	Treatment of chloroquine-resistant <i>Plasmodium vivax</i> with chloroquine and primaquine or halofantrine	<i>J Infect Dis</i>	171		1678–1682	7769318
Baird	1997	In vivo resistance to chloroquine by <i>Plasmodium vivax</i> and <i>Plasmodium falciparum</i> at Nabire, Irian Jaya, Indonesia	<i>Am J Trop Med Hyg</i>	56	6	627–631	9230793
Baird	2002	Chloroquine for the treatment of uncomplicated malaria in Guyana	<i>Ann Trop Med Parasitol</i>	96	4	339–348	12171615
Baird	1996 a	Chloroquine sensitive <i>Plasmodium falciparum</i> and <i>P. vivax</i> in Central Java, Indonesia	<i>Trans R Soc Trop Med Hyg</i>	90		412–413	8882191
Baird	1996 b	Survey of resistance to chloroquine by <i>Plasmodium vivax</i> in Indonesia	<i>Trans R Soc Trop Med Hyg</i>	90		409–411	8882190
Baird	1996 c	Survey of resistance to chloroquine of falciparum and vivax malaria in Palawan, The Philippines	<i>Trans R Soc Trop Med Hyg</i>	90		413–414	8882192
Barnadas	2008 a	<i>Plasmodium vivax</i> resistance to chloroquine in Madagascar: clinical efficacy and polymorphisms in <i>pvm-dr1</i> and <i>pvcrt-o</i> genes	<i>Antimicrob Agents Chemother</i>	52	12	4233–4240	18809933
Barnadas	2008 b	<i>Plasmodium vivax dhfr</i> and <i>dhps</i> mutations in isolates from Madagascar and therapeutic response to sulphadoxine-	<i>Malaria J</i>	7	35	35	18302746

Castillo	2002	pyrimethamine Assessment of therapeutic response of <i>Plasmodium vivax</i> and <i>Plasmodium falciparum</i> to chloroquine in a Malaria transmission free area in Colombia	<i>Mem Inst Oswaldo Cruz</i>	97	4	559–562	12118291
Congpuong	2002	Sensitivity of <i>Plasmodium vivax</i> to chloroquine in Sa Kaeo Province, Thailand	<i>Acta Trop</i>	83		117–121	12088852
Congpuong	2011	In vivo sensitivity monitoring of chloroquine for the treatment of uncomplicated vivax malaria in four bordered provinces of Thailand during 2009–2010	<i>J Vector Borne Dis</i>	48	4	190–196	22297279
Dao	2007	Vivax malaria: preliminary observations following a shorter course of treatment with artesunate plus primaquine	<i>Trans R Soc Trop Med Hyg</i>	101		534–539	17368694
Darlow	1982	Sulfadoxine- pyrimethamine for the treatment of acute malaria in children of Papua New Guinea. II.	<i>Am J Trop Med Hyg</i>	31	1	10–13	7036765
de Santana Filho	2007	<i>Plasmodium vivax</i> Chloroquine-resistant <i>Plasmodium vivax</i> , Brazilian Amazon	<i>Emerg Infect Dis</i>	13	7	1125– 1127	18214203
Dilmec	2010	Monitoring of failure of chloroquine treatment of <i>Plasmodium vivax</i> using polymerase chain reaction in Sanliurfa province, Turkey	<i>Parasitol Res</i>	106		783–788	20140453
Dixon	1985	A clinical trial of mefloquine in the treatment of <i>Plasmodium vivax</i> malaria.	<i>Am J Trop Med Hyg</i>	34	3	435–437	3890575
Dunne	2005	A double blind, randomized study of azithromycin compared with chloroquine for the treatment of <i>Plasmodium vivax</i> malaria	<i>Am J Trop Med Hyg</i>	73	6	1108– 1111	16354821
Ebisawa	1986	A combination of sulfamonomethoxine and pyrimethamine vs. other drugs for the treatment of malaria	<i>Jpn J Exp Med</i>	56	5	213–219	3543442

Eibach	2012	Therapeutic efficacy of artemether-lumefantrine for <i>Plasmodium vivax</i> infections in a prospective study in Guyana	<i>Malaria J</i>	11		e347	23083017
Fryauff	1997	Survey of in vivo sensitivity to chloroquine by <i>Plasmodium falciparum</i> and <i>P. vivax</i> in Lombok, Indonesia	<i>Am J Trop Med Hyg</i>	56	2	241–244	9080887
Fryauff	1999	In vivo responses to antimalarials by <i>Plasmodium falciparum</i> and <i>Plasmodium vivax</i> from isolated Gag Island off northwest Irian Jaya, Indonesia	<i>Am J Trop Med Hyg</i>	60	4	542–546	10348226
Fryauff	2002	The drug sensitivity and transmission dynamics of human malaria on Nias Island, North Sumatra, Indonesia	<i>Ann Trop Med Parasitol</i>	96	5	447–462	12194705
Fryauff	1998 ^a	Chloroquine-resistant <i>Plasmodium vivax</i> in transmigration settlements of West Kalimantan, Indonesia	<i>Am J Trop Med Hyg</i>	59	4	513–518	9790420
Fryauff	1998 ^b	Survey of resistance in vivo to chloroquine of <i>Plasmodium falciparum</i> and <i>P. vivax</i> in North Sulawesi, Indonesia	<i>Trans R Soc Trop Med Hyg</i>	92		82–83	9692162
Ganguly	2013	In vivo therapeutic efficacy of chloroquine alone or in combination with primaquine in vivax malaria in Kolkata, West Bengal, India and polymorphism in <i>pvm-dr1</i> and <i>pvcrt-0</i> genes	<i>Antimicrob Agents Chemother</i>	57	3	1246–1251	23262997
Genton	2005	Parasitological and clinical efficacy of standard treatment regimens against <i>Plasmodium falciparum</i> , <i>P. vivax</i> and <i>P. malariae</i> in Papua New Guinea	<i>P N G Med J</i>	48	3	141–150	17212060
Gogtay	1999	Efficacy of 5- and 14-day primaquine regimen in the prevention of relapses in <i>Plasmodium vivax</i> infections	<i>Ann Trop Med Parasitol</i>	93		809–812	10715673
Guthmann	2008	<i>Plasmodium vivax</i> resistance to chloroquine in Dawei, southern	<i>Trop Med Int Health</i>	13		91–98	18291007

Hamed	1999	Myanmar <i>Plasmodium vivax</i> malaria in southeast Iran in 1999–2001: establishing the response to chloroquine in vitro and in vivo	<i>Southeast Asian J Trop Med Public Health</i>	33	3	512–517	12693585
Hamed	2004	Therapeutic efficacy of artesunate in <i>Plasmodium vivax</i> malaria in Thailand	<i>Southeast Asian J Trop Med Public Health</i>	35	3	570–574	15689068
Hapuarachchi	2004	Chloroquine resistant falciparum malaria among security forces personnel in the Northern Province of Sri Lanka	<i>Ceylon Med J</i>	49	2	47–51	15334798
Harinasuta	1985	Trials of mefloquine in vivax and of mefloquine plus ‘fansidar’ in falciparum malaria	<i>Lancet</i>	8434		885–888	2858743
Hasugian	2007	Dihydroartemisinin-piperaquine vs. artesunate-amodiaquine: superior efficacy and posttreatment prophylaxis against multidrug-resistant <i>Plasmodium falciparum</i> and <i>Plasmodium vivax</i> malaria	<i>Clin Infect Dis</i>	44		1067–74	17366451
Hasugian	2009	In vivo and in vitro efficacy of amodiaquine monotherapy for treatment of infection by chloroquine-resistant <i>Plasmodium vivax</i>	<i>Antimicrob Agents Chemother</i>	53	3	1094–1099	19104023
Heidari	2012	In vivo susceptibility of <i>Plasmodium vivax</i> to chloroquine in southeastern Iran	<i>Iran J Parasitol</i>	7	2	81–84	23109940
Hwang	2013	In vivo efficacy of artemether-lumefantrine and chloroquine against <i>Plasmodium vivax</i> : a randomized open label trial in central Ethiopia	<i>PLoS One</i>	8	5	e63433	23717423
Jagota	1993	Halofantrine in the treatment of acute malaria: a multi-center study in 268 patients	<i>Curr Med Res Opin</i>	13	3	140–144	8222741
Kaneko	1999	Intrinsic efficacy of proguanil against falciparum and vivax malaria independent of the metabolite	<i>J Infect Dis</i>	179		974–979	10068594

Karunajeewa	2008	cycloguanil A trial of combination antimalarial therapies in children from Papua New Guinea.	<i>N Engl J Med</i>	359	24	2545	19064624
Ketema	2009	Chloroquine-resistant <i>Plasmodium vivax</i> malaria in Serbo town, Jimma zone, south-west Ethiopia	<i>Malaria J</i>	8		177	19642976
Ketema	2011	Therapeutic efficacy of chloroquine for treatment of <i>Plasmodium vivax</i> malaria cases in Halaba district, south Ethiopia	<i>Parasit Vectors</i>	4	46	1–7	21453465
Khan	2006	Efficacy and safety of halofantrine in Pakistani children and adults with malaria caused by <i>P. falciparum</i> and <i>P. vivax</i>	<i>Southeast Asian J Trop Med Public Health</i>	37	4	613–618	17121283
Kinzer	2010	Active case detection, treatment of falciparum malaria with combined chloroquine and sulphadoxine/pyrimethamine and vivax malaria with chloroquine and molecular markers of antimalarial resistance in the Republic of Vanuatu	<i>Malaria J</i>	9		89	20370920
Kolaczinski	2007	Sulfadoxine-pyrimethamine plus artesunate compared with chloroquine for the treatment of vivax malaria in areas co-endemic for <i>Plasmodium falciparum</i> and <i>P. vivax</i> : a randomised non-inferiority trial in eastern Afghanistan	<i>Trans R Soc Trop Med Hyg</i>	101		1081–1087	17707447
Krudson	2007	Clinical efficacy of chloroquine vs. artemether-lumefantrine for <i>Plasmodium vivax</i> treatment in Thailand	<i>Korean J Parasitol</i>	45	2	111–114	17570973
Kurcer	2004	Efficacy of chloroquine in the treatment of <i>Plasmodium vivax</i> malaria in Turkey	<i>Ann Trop Med Parasitol</i>	98	5	447–451	15257793
Kurcer	2006	The decreasing efficacy of chloroquine in the treatment of <i>Plasmodium vivax</i> malaria, in Sanliurfa, south-eastern Turkey	<i>Ann Trop Med Parasitol</i>	100	2	109–113	16492358

Lacy	2002	Atovaquone/proguanil therapy for <i>Plasmodium falciparum</i> and <i>Plasmodium vivax</i> malaria in Indonesians who lack clinical immunity	<i>Clin Infect Dis</i>	35		92–95	12384852
Lal	1982	A comparative trial of oral chloroquine and oral co-trimoxazole in vivax malaria in children	<i>Am J Trop Med Hyg</i>	31	3	438–440	7044160
Leang	2013	Efficacy of dihydroartemisinin-piperaquine for the treatment of uncomplicated <i>Plasmodium falciparum</i> and <i>Plasmodium vivax</i> in Cambodia, 2008–2010	<i>Antimicrob Agents Chemother</i>	57	9	818–826	23208711
Lee	2009	Biological resistance of hydroxychloroquine for <i>Plasmodium vivax</i> malaria in the Republic of Korea	<i>Am J Trop Med Hyg</i>	81	4	600–604	19815873
Leslie	2007	Sulfadoxine-pyrimethamine, chlorproguanil-dapsone, or chloroquine for the treatment of <i>Plasmodium vivax</i> malaria in Afghanistan and Pakistan: a randomized controlled trial	<i>JAMA</i>	297	20	2201–2209	17519409
Leslie	2008	A randomized controlled trial of 8 weeks, once weekly primaquine regimen to prevent relapse of <i>Plasmodium vivax</i> in Northwest Frontier Province, Pakistan	<i>PLoS One</i>	3	8	2861	18682739
Li	1994	Clinical trials of artemisinin and its derivatives in the treatment of malaria in China	<i>Trans R Soc Trop Med Hyg</i>	88		5–6	8053027
Lim	1999	Response to chloroquine of <i>Plasmodium vivax</i> among South Korean soldiers	<i>Ann Trop Med Parasitol</i>	93	6	565–568	10707102
Liu	2013	Artemisinin-naphthoquine combination vs. chloroquine-primaquine to treat vivax malaria: an open-label randomized	<i>Malaria J</i>	12	409	409	24215565

Llanos-Cuentas	2013	and non-inferiority trial in Yunnan Province, China Tafenoquine plus chloroquine for the treatment and relapse prevention of <i>Plasmodium vivax</i> malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study Efficacy of two vs. three-day regimens of dihydroartemisinin-piperaquine for uncomplicated malaria in military personnel in northern Cambodia: an open-label randomized trial	<i>Lancet</i>	383	9922	1049–1058	24360369
Lon	2014	Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand	<i>PLoS One</i>	9	3	e93138	24667662
Looareesuwan	1996	Chloroquine sensitivity of <i>Plasmodium vivax</i> in Thailand	<i>Am J Trop Med Hyg</i>	54	1	62–66	8651372
Looareesuwan	1999 a	Atovaquone and proguanil hydrochloride followed by primaquine for treatment of <i>Plasmodium vivax</i> malaria in Thailand	<i>Ann Trop Med Parasitol</i>	93	3	225–230	10562823
Looareesuwan	1999 b	Treatment of vivax malaria on the western border of Thailand	<i>Trans R Soc Trop Med Hyg</i>	93		637–640	10717754
Luxemburger	1999	Correlation between <i>Plasmodium vivax</i> variants in Belém, Pará State, Brazil and symptoms and clearance of parasitaemia	<i>Trans R Soc Trop Med Hyg</i>	93		433–438	10674098
Machado	2003	Chloroquine or sulfadoxine-pyrimethamine for the treatment of uncomplicated, <i>Plasmodium falciparum</i> malaria during an epidemic in Central Java, Indonesia	<i>Braz J Infect Dis</i>	7	3	175–177	14499040
Maguire	2002	Mefloquine is highly	<i>Ann Trop Med Parasitol</i>	96	7	655–668	12537627
Maguire	2006		<i>Clin</i>	42	8	1067–	16575721

		efficacious against chloroquine-resistant <i>Plasmodium vivax</i> malaria and <i>Plasmodium falciparum</i> malaria in Papua, Indonesia	<i>Infect Dis</i>			1072	
Marfurt	2007	Low efficacy of amodiaquine or chloroquine plus sulfadoxine-pyrimethamine against <i>Plasmodium falciparum</i> and <i>P. vivax</i> malaria in Papua New Guinea	<i>Am J Trop Med Hyg</i>	77	5	947–954	17984359
Marques	2014	<i>Plasmodium vivax</i> chloroquine resistance and anemia in the western Brazilian Amazon	<i>Antimicrob Agents Chemother</i>	58	1	342–347	24165179
McGready	2002	The effects of quinine and chloroquine antimalarial treatments in the first trimester of pregnancy	<i>Trans R Soc Trop Med Hyg</i>	96	2	180–184	12055810
Mishra	2012	Monitoring antimalarial drug resistance in India via sentinel sites: outcomes and risk factors for treatment failure, 2009–2010	<i>Bull World Health Organ</i>	90	12	895–904	23284195
Mohapatra	2002	Atypical manifestation of <i>Plasmodium vivax</i> malaria	<i>Indian J Malariol</i>	39	40940	18–25	14686106
Muhamad	2011	Monitoring of clinical efficacy and in vitro sensitivity of <i>Plasmodium vivax</i> to chloroquine in area along Thai Myanmar border during 2009–2010	<i>Malaria J</i>	10		44	21324161
Murphy	1993	Vivax malaria resistant to treatment and prophylaxis with chloroquine	<i>Lancet</i>	341	8837	96–100	8093414
Nandy	2003	Monitoring the chloroquine sensitivity of <i>Plasmodium vivax</i> from Calcutta and Orissa, India	<i>Ann Trop Med Parasitol</i>	97	3	215–220	12803853
Nateghpour	2007	Evaluation of sensitivity of <i>Plasmodium vivax</i> to chloroquine	<i>Iran J Public Health</i>	36	3	60–63	Non-PubMed
Nguyen	1993	Treatment of malaria in Vietnam with oral artemisinin	<i>Am J Trop Med Hyg</i>	48	3	398–402	8470777
Osorio	2007	Assessment of the efficacy of antimalarial drugs in Tarapaca, in the Colombian Amazon basin [in Spanish]	<i>Biomedica</i>	27	1	133–140	17546230

Phan	2002	Artemisinin or chloroquine for blood stage <i>Plasmodium vivax</i> malaria in Vietnam	<i>Trop Med Int Health</i>	7	10	858–864	12358621
Phyo	2011	Dihydroartemisinin-piperaquine vs. chloroquine in the treatment of <i>P. vivax</i> malaria in Thailand: a randomized controlled trial	<i>Clin Infect Dis</i>	53		977–984	22002979
Pinto	2003	Assessment of chloroquine single dose treatment of malaria due to <i>Plasmodium vivax</i> in Brazilian Amazon	<i>Rev Inst Med Trop Sao Paulo</i>	45	6	327–331	14762633
Poravuth	2011	Pyronaradine-artesunate vs. chloroquine in patients with acute <i>P. vivax</i> malaria: a randomized double-blind, non-inferiority trial	<i>PLoS One</i>	6	1	14501	21267072
Potkar	1995	Resurgence of malaria and drug resistance in <i>Plasmodium falciparum</i> and <i>Plasmodium vivax</i> species in Bombay	<i>J Assoc Physicians India</i>	43	5	336–338	9081964
Pukrittayakamee	2000	Therapeutic responses to different antimalarial drugs in vivax malaria.	<i>Antimicrob Agents Chemother</i>	44		1680–1685	10817728
Pukrittayakamee	2001	Therapeutic responses to antibacterial drugs in vivax malaria	<i>Trans R Soc Trop Med Hyg</i>	95		524–528	11706666
Pukrittayakamee	2010	A comparison of two short-course primaquine regimens for the treatment and radical cure of <i>Plasmodium vivax</i> malaria in Thailand	<i>Am J Trop Med Hyg</i>	82	4	542–547	20348496
Pukrittayakamee	1994a	Blood stage antimalarial efficacy of primaquine in <i>Plasmodium vivax</i> malaria	<i>J Infect Dis</i>	169		932–935	8133114
Pukrittayakamee	1994b	Antimalarial effects of rifampin in <i>Plasmodium vivax</i> malaria	<i>Antimicrob Agents Chemother</i>	38	3	551–514	8203846
Rajgor	2003	Efficacy of a 14 day primaquine regimen in preventing relapses in patients with <i>Plasmodium vivax</i> malaria in Mumbai, India	<i>Trans R Soc Trop Med Hyg</i>	97		438–440	15259476
Rao	1993	Efficacy and safety of halofantrine in acute	<i>J Assoc Physicians</i>	41	8	507–508	8294355

		malaria	<i>s India</i>				
Ratcliff	2007 a	Therapeutic response of multidrug-resistant <i>Plasmodium falciparum</i> and <i>P. vivax</i> to chloroquine and sulfadoxine—pyrimethamine in southern Papua, Indonesia	<i>Trans R Soc Trop Med Hyg</i>	101		351–359	17028048
Ratcliff	2007 b	Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison	<i>Lancet</i>	369		757–765	17336652
Rios	2013	Ten years of chloroquine efficacy for uncomplicated <i>Plasmodium vivax</i> malaria treatment, Turbo, Antioquia, 2002 and 2011	<i>Biomedica</i>	33	3	429–438	24652179
Rowland	1999	Randomized controlled trials of 5- and 14-days primaquine therapy against relapses of vivax malaria in an Afghan refugee settlement in Pakistan	<i>Trans R Soc Trop Med Hyg</i>	93	6	641–643	10717755
Ruebush	2003	Chloroquine-resistant <i>Plasmodium vivax</i> malaria in Peru	<i>Am J Trop Med Hyg</i>	69	5	548–552	14695094
Saravu	2012	<i>Plasmodium vivax</i> remains responsive to chloroquine with primaquine treatment regimen: a prospective cohort study from tertiary care teaching hospital in southern India	<i>Trop Doc</i>	42	3	163–164	22516030
Shalini	2014	Chloroquine efficacy studies confirm drug susceptibility of <i>Plasmodium vivax</i> in Chennai, India	<i>Malaria J</i>	13	1	129	24685286
Silachamroon	2003	Clinical trial of oral artesunate with or without high-dose primaquine for the treatment of vivax malaria in Thailand	<i>Am J Trop Med Hyg</i>	69	1	14–18	12932090
Singh	2000	Emergence of chloroquine-resistant vivax malaria in south Bihar (India)	<i>Trans R Soc Trop Med Hyg</i>	94		327	10975013

Soto	2001	<i>Plasmodium vivax</i> clinically resistant to chloroquine in Colombia Therapeutic responses of <i>Plasmodium vivax</i> and <i>P. falciparum</i> to chloroquine, in an area of western India where <i>P. vivax</i> predominates Very high risk of therapeutic failure with chloroquine for uncomplicated <i>Plasmodium falciparum</i> and <i>P. vivax</i> malaria in Indonesian Papua	<i>Am J Trop Med Hyg</i>	65	2	90–93	11508397
Srivastava	2008	Resistance to chloroquine by <i>Plasmodium vivax</i> at Alor in the Lesser Sundas Archipelago in eastern Indonesia Evaluation of chloroquine therapy for <i>vivax</i> and <i>falciparum</i> malaria in southern Sumatra, western Indonesia	<i>Ann Trop Med Parasitol</i>	102	66	471–480	18782486
Sumawinata	2003	Clinical response and susceptibility in vitro of <i>Plasmodium vivax</i> to the standard regimen of chloroquine in Thailand Clinical-parasitological response and in-vitro sensitivity of <i>Plasmodium vivax</i> to chloroquine and quinine on the western border of Thailand	<i>Am J Trop Med Hyg</i>	68	4	416–420	12875290
Sutanto	2009	Assessing drug sensitivity of <i>Plasmodium vivax</i> to halofantrine or chloroquine in southern, central Vietnam using an extended 28-day in vivo test and polymerase chain reaction genotyping Chloroquine/doxycycline combination vs. chloroquine alone, and doxycycline alone for the treatment of <i>Plasmodium falciparum</i> and <i>Plasmodium vivax</i> malaria in northeastern Irian Jaya, Indonesia	<i>Am J Trop Med Hyg</i>	81	2	338–342	19635895
Sutanto	2010	Chloroquine-resistant <i>Plasmodium vivax</i>	<i>Malaria J</i>	9	52		20152016
Tan	1995		<i>Trans R Soc Trop Med Hyg</i>	89		426–429	7570887
Tasanor	2006		<i>Trans R Soc Trop Med Hyg</i>	100		410–418	16497347
Taylor	2000		<i>Am J Trop Med Hyg</i>	62	6	693–697	11304056
Taylor	2001		<i>Am J Trop Med Hyg</i>	64	5	223–228	11463107
Teka	2008		<i>Malaria J</i>	7	220	1–8	18959774

Than	1995	malaria in Debre Zeit, Ethiopia Development of resistance to chloroquine by <i>Plasmodium vivax</i> in Myanmar Therapeutic efficacies of artesunate-sulfadoxine-pyrimethamine and chloroquine-sulfadoxine-pyrimethamine in vivax malaria pilot studies: relationship to <i>Plasmodium vivax dhfr</i> mutations	<i>Trans R Soc Trop Med Hyg</i>	89		307–308	7660445
Tjitra	2002	Efficacy and safety of artemisinin-naphthoquine vs. dihydroartemisinin-piperaquine in adult patients with uncomplicated malaria: a multi-center study in Indonesia Adequate clinical and parasitological <i>Plasmodium vivax</i> response to chloroquine in Colombia (Turbo, Antioquia), 2001 [in Spanish]	<i>Antimicrob Agents Chemother</i>	46	12	3947–3953	12435700
Tjitra	2012	Failure of chloroquine treatment of malaria in the highlands of Ethiopia Therapeutic efficacy of chloroquine in <i>Plasmodium vivax</i> from areas with different epidemiological patterns in India and their <i>Pvdhfr</i> gene mutation pattern Clinical efficacy of chloroquine followed by primaquine for <i>Plasmodium vivax</i> treatment in Azerbaijan	<i>Malaria J</i>	1		e153	22554203
Trukillo	2002	Assessment of therapeutic efficacy of chloroquine for vivax malaria in Thailand In-vivo sensitivity of <i>Plasmodium vivax</i> isolates from Rondônia (western Amazon region, Brazil) to regimens including chloroquine	<i>Infectio</i>	6	1	21–26	Non-PubMed
Tulu	1996		<i>Trans R Soc Trop Med Hyg</i>	90		556–557	8944273
Valecha	2006		<i>Trans R Soc Trop Med Hyg</i>	100		831–837	16513151
Valibayov	2003		<i>Acta Trop</i>	88		99–102	12943984
Vijaykadga	2004		<i>Southeast Asian J Trop Med Public Health</i>	35	3	566–569	15689067
Villalobos	2000		<i>Ann Trop Med Parasitol</i>	94	8	749–758	11214093

Walsh	1999	and primaquine Randomized dose- ranging study of the safety and efficacy of WR 238605 (tafenoquine) in the prevention of relapse of <i>Plasmodium vivax</i> malaria in Thailand Randomized trial of 3- dose regimens of tafenoquine (WR238605) vs. low-dose primaquine for preventing <i>Plasmodium vivax</i> malaria relapse	<i>J Infect Dis</i>	180	4	1282– 1287	10479159
Walsh	2004	Efficacy of primaquine regimens for primaquine- resistant <i>Plasmodium vivax</i> malaria in Thailand Radical curative efficacy of 5 day regimen of primaquine for treatment <i>Plasmodium vivax</i> malaria in India	<i>Clin Infect Dis</i>	39		1095– 1103	15486831
Wilairatana	1999	Efficacy of DB289 in Thai patients with <i>Plasmodium vivax</i> or acute, uncomplicated <i>Plasmodium falciparum</i> infections	<i>Am J Trop Med Hyg</i>	61	6	973–977	10674681
Yadav	2002	Therapeutic efficacy of chloroquine and chloroquine plus primaquine for the treatment of <i>Plasmodium vivax</i> in Ethiopia Confirmed vivax resistance to chloroquine and effectiveness of artemether-lumefantrine for the treatment of vivax malaria in Ethiopia	<i>J Parasitol</i>	88	5	1042– 1044	12435158
Yeramian	2005	Blood stage of <i>Plasmodium vivax</i> in central China is still susceptible to chloroquine plus primaquine combination therapy	<i>J Infect Dis</i>	192	2	319–322	15962227
Yeshiwondim	2010		<i>Acta Trop</i>	113		105–113	19835832
Yohannes	2011		<i>Am J Trop Med Hyg</i>	84	1	137–140	21212216
Zhu	2013		<i>Am J Trop Med Hyg</i>	89	1	184–187	23669232

SUPPLEMENTAL ANNEX B

Trials of different doses of primaquine and control groups from clinical trials conducted from 1953 to 2011 (supplemental to John and others¹⁰⁴)

First author	Year of publication	Country	Partner drug	Duration of treatment (days)	Total primaquine dose (mg/kg)	Primaquine supervision	Duration of follow-up (days)	Sample size	Recurrence rate (%) of <i>Plasmodium vivax</i> at the end of the study
Very low-dose primaquine (≤ 2.5 mg/kg total dose)									
Baird	1995	Indonesia	Chloroquine	3	2.50	Not stated	28	19	15.8
Dixon	1985	Thailand	Chloroquine	5	1.25	Not stated	28	40	0.0
Krudsod	2008	Thailand	Artesunate	5	2.50	Not stated	28	60	15.0
Di Lorenzo	1953	United States, Korea	Chloroquine	7	1.75	Not stated	90	31	3.0
Villalobos-Salcedo	2000	Brazil	Chloroquine	5	2.50	All doses	90	30	20.0
Alving	1960	United States, Chesson	Chloroquine	28	2.00	Not stated	120	41	90.0
Carmona-Fonseca	2009	Columbia	Chloroquine	3	1.75	All doses	120	26	50.0
Carmona-Fonseca	2009	Columbia	Chloroquine	3	2.50	All doses	120	26	57.7
Abdon	2001	Brazil	Chloroquine	5	2.50	All doses	180	40	20.0
Alvarez	2006	Columbia	Chloroquine	7	1.75	All doses	180	62	41.9
Alvarez	2006	Columbia	Chloroquine	3	0.75	All doses	180	65	49.2
Bergonzoli	2000	Nicaragua, Costa Rica	Chloroquine	5	2.00	All doses	180	30	0.0
Bergonzoli	2000	Nicaragua, Costa Rica	Chloroquine	1	0.75	All doses	180	25	4.0
Da Silva	2003	Brazil	Chloroquine	5	2.50	Not stated	180	26	15.4
Da Silva	2003	Brazil	Artesunate (100 mg)	5	2.50	Not stated	180	25	16.0
Da Silva	2003	Brazil	Artesunate (200 mg)	5	2.50	Not stated	180	20	25.0
Da Silva	2003	Brazil	Artesunate (150 mg)	5	2.50	Not stated	180	20	25.0
Fernandopulle	2003	Sri Lanka	Not stated	5	1.25	All doses	180	6	83.3
Gogtay	1998	India	Chloroquine	5	1.25	All doses	180	0	15.0
Gogtay	1999	India	Chloroquine	5	1.25	All doses	180	62	25.8
Saint-Yves	1977	PNG	Chloroquine	1	0.75	All doses	180	9	67.0
Contacos	1973	United States, West Pakistan	Chloroquine	5	1.25	Not stated	200	5	100.0

Singh	1990	India	Chloroquine	5	1.25	Not stated	240	995	13.2
Cedillos	1978	El Salvador	Amodiaquine	5	1.25	Part supervised	270	90	21.1
Cedillos	1978	El Salvador	Amodiaquine	1	0.75	Part supervised	270	67	23.9
Mendoza	1963	Mexico	Chloroquine	5	1.25	All doses	270	389	20.6
Rowland	1999	Pakistan	Chloroquine	5	1.25	All doses	300	250	51.2
Cooper	1953	United States, Chesson	Quinine	14	2.33	Not stated	350	34	65.0
Cooper	1953	United States, Chesson	Chloroquine	7	2.33	Not stated	350	10	80.0
Thaeler	1953	Nicaragua	Chloroquine	14	2.33	Not stated	360	121	0.0
Adak	2001	India	Chloroquine	5	1.25	All doses	365	220	26.8
Appavoo	1984	India	Chloroquine	3	1.25	Not stated	365	425	3.8
Prasad	1991	India	Chloroquine	5	1.25	All doses	365	883	2.0
Roy	1977	India	Chloroquine	5	1.25	Not stated	365	6,393	1.3
Roy	1979	India	Chloroquine	5	1.25	All doses	365	1,389	0.7
Sharma	1973	India	Chloroquine	5	1.25	All doses	365	140	9.3
Yadav	2002	India	Chloroquine	5	1.25	Not stated	365	759	6.5
Sinha	1989	India	Chloroquine	5	1.25	All doses	395	725	6.9
Basavaraj	1960	India	Chloroquine	5	1.25	Not stated	480	563	6.0
Dua	2001	India	Chloroquine	5	1.25	Not stated	540	5,541	9.2
Srivastava	1996	India	Chloroquine	5	1.25	Not stated	540	173	5.8
Prasad	1991	India	Chloroquine	5	1.25	All doses	720	1,439	4.0
Prasad	1991	India	Chloroquine	5	1.25	All doses	1,080	2,484	5.7
Prasad	1991	India	Chloroquine	5	1.25	All doses	1,440	8,914	23.2
Low-dose primaquine (> 2.5 to < 5.0 mg/kg total dose)									
Looareesuwan	1999a	Thailand	Chloroquine	14	3.5	All doses	28	441	0.5
Singh	2000	India	Chloroquine	14	3.5	Part supervised	28	75	16.0
Buchachart	2001	Thailand	Chloroquine	14	3.5	Not stated	28	364	0.0
Congpuong	2002	Thailand	Chloroquine	14	3.5	Not stated	28	26	0.0
Hamedi	2002	Iran	Chloroquine	14	3.5	All doses	28	39	0.0
Valibayov	2003	Azerbaijan	Chloroquine	14	3.5	Not stated	28	143	0.0
Hamedi	2004	Thailand	Artesunate	14	3.5	All doses	28	42	4.8
Yeramian	2005	Thailand	DB289	14	3.5	Not stated	28	9	11.1
Krudsood	2006	Thailand	Chloroquine	7	3.5	All doses	28	68	1.5
Maguire	2006	Indonesia	Mefloquine	14	3.5	All doses	28	310	1.3
Maguire	2006	Indonesia	Chloroquine	14	3.5	All doses	28	249	21.2
Tasanor	2006	Thailand	Chloroquine	14	3.5	All doses	28	24	0.0

Tasanor	2006	Thailand	Quinine	14	3.5	All doses	28	23	0.0
Krudsood	2007	Thailand	Chloroquine	14	3.5	Not stated	28	42	0.0
Krudsood	2007	Thailand	Artemether– lumefantrine	14	3.5	Not stated	28	38	2.6
Krudsood	2008	Thailand	Artesunate	9	4.5	Not stated	28	56	4.0
Krudsood	2008	Thailand	Artesunate	7	3.5	Not stated	28	57	11.0
Lee	2009	Republic of Korea	Chloroquine	14	3.5	Part supervised	28	108	0.0
Pukrittayakamee	2010	Thailand	None	7	3.5	Not stated	28	31	30.0
Pukrittayakamee	1994b	Thailand	Chloroquine	14	3.5	Not stated	28	25	0.0
Pukrittayakamee	1994b	Thailand	None	14	3.5	Not stated	28	30	10.0
Pukrittayakamee	2000	Thailand	Chloroquine	14	3.5	Not stated	28	22	0.0
Pukrittayakamee	2000	Thailand	None	14	3.5	Not stated	28	26	11.5
Pukrittayakamee	1994a	Thailand	Chloroquine	14	3.5	Not stated	30	20	0.0
Pukrittayakamee	1994a	Thailand	Rifampicin	14	3.5	Not stated	30	20	5.0
Machado	2003	Brazil	Chloroquine	14	3.5	Not stated	30	30	0.0
Muhamed	2011	Thailand	Chloroquine	14	3.5	Part supervised	42	130	0.0
Luxemburger	1999	Thailand	Chloroquine	14	3.5	All doses	63	43	7.0
Villalobos- Salcedo	2000	Brazil	Chloroquine	14	3.5	All doses	90	31	6.5
Takeuchi	2010	Thailand	Chloroquine	14	3.5	All doses	90	90	3.3
Takeuchi	2010	Thailand	Chloroquine	14	3.5	Unsupervise d	90	97	12.4
Maneeboonyang	2011	Thailand	Chloroquine	14	3.5	All doses	90	43	0.0
Maneeboonyang	2011	Thailand	Chloroquine	14	3.5	Unsupervise d	90	33	15.1
Tan-ariya	1995	Thailand	Chloroquine	14	3.5	Part supervised	100	50	12.0
Alving	1953	United States, Korea	Chloroquine	14	3.5	Not stated	120	348	0.0
Alving	1960	United States, Chesson	Chloroquine	14	3.5	Not stated	120	60	27.0

Alving	1960	United States, Chesson	Chloroquine	28	4.0	Not stated	120	20	30.0
Alving	1960	United States, Chesson	Chloroquine	28	3.0	Not stated	120	15	40.0
Alving	1960	United States, Chesson	Chloroquine	56	4.0	Not stated	120	61	55.7
Carmona-Fonseca	2009	Columbia	Chloroquine	14	3.5	All doses	120	66	15.2
Carmona-Fonseca	2009	Columbia	Chloroquine	3	3.5	All doses	120	63	58.7
Yeshiwondim	2010	Ethiopia	Chloroquine	14	3.5	All doses	157	132	3.0
Walsh	2004	Thailand	Chloroquine	14	3.5	All doses	168	12	25.0
Coatney	1953	United States, Korea	None	14	3.5	Not stated	180	294	0.0
Martelo	1969	United States, Vietnam	Chloroquine	14	3.5	Not stated	180	21	14.3
Fisher	1970	United States, Vietnam	Chloroquine	14	3.5	All doses	180	133	7.5
Gogtay	1999	India	Chloroquine	14	3.5	All doses	180	63	0.0
Bergonzoli	2000	Nicaragua, Costa Rica	Chloroquine	14	3.5	All doses	180	26	0.0
Bergonzoli	2000	Nicaragua, Costa Rica	Chloroquine	9	2.8	All doses	180	28	3.6
Abdon	2001	Brazil	Chloroquine	7	3.5	All doses	180	39	0.0
Abdon	2001	Brazil	Chloroquine	14	3.5	All doses	180	40	5.0
Duarte	2001	Brazil	Chloroquine	14	3.5	Part supervised	180	50	14.0
Da Silva	2003	Brazil	Artesunate (100 mg)	7	3.5	Not stated	180	22	0.0
Da Silva	2003	Brazil	Chloroquine	7	3.5	Not stated	180	25	4.0
Da Silva	2003	Brazil	Artesunate (200 mg)	7	3.5	Not stated	180	20	5.0
Da Silva	2003	Brazil	Artesunate (150 mg)	7	3.5	Not stated	180	24	20.8
Rajgor	2003	India	Chloroquine	14	3.5	All doses	180	103	5.8
Alvarez	2006	Columbia	Chloroquine	15	3.5	All doses	180	64	18.8
Mendoza	1963	Mexico	Chloroquine	14	3.5	All doses	270	363	10.2
Miller	1974	United States, Chesson	Chloroquine	14	3.5	Not stated	270	57	3.5
Li	1999	China	Chloroquine	8	3.0	All doses	270	35	22.9
Leslie	2004	Pakistan	Chloroquine	14	3.5	All doses	270	210	19.0
Leslie	2004	Pakistan	Chloroquine	14	3.5	All doses	270	173	19.7
Smoak	1997	United States, Somalia	Chloroquine/quinine	14	3.5	Part supervised	300	32	25.0
Smoak	1997	United States, Somalia	Chloroquine/quinine	14	3.5	Part supervised	300	28	64.2
Rowland	1999	Pakistan	Chloroquine	14	3.5	All doses	300	100	32.0
Orjuela-Sanchez	2009	Brazil	Chloroquine	7	3.5	Part supervised	336	87	71.5
Cooper	1953	United States, Chesson	Quinine	14	4.7	Not stated	350	34	15.0

Cooper	1953	United States, Chesson	Chloroquine	7	3.5	Not stated	350	10	90.0
Orjuela-Sanchez	2009	Brazil	Chloroquine	7	3.5	Part supervised	355	77	36.6
Thaeler	1953	Nicaragua	Chloroquine	14	3.5	Not stated	360	151	0.0
Thaeler	1953	Nicaragua	Chloroquine	14	4.7	Not stated	360	49	0.0
Alving	1955	United States, Chesson	Quinine	14	3.5	Not stated	365	19	5.3
Alving	1955	United States, Chesson	Chloroquine	14	3.5	Not stated	365	19	26.3
Alving	1955	United States, Chesson	None	14	3.5	Not stated	365	19	78.9
Saint-Yves	1977	PNG	Chloroquine	14	3.50	All doses	365	10	0.0
Schwartz	2000	Israel	Chloroquine	14	3.5	Not stated	365	15	33.3
Bunnag	1994	Thailand	Chloroquine	14	3.5	Not stated	540	81	8.6
Jelinek	1995	Germany	Chloroquine	14	3.5	Not stated	540	56	12.5
Fang	1999	Taiwan	Chloroquine	14	3.5	Not stated	540	12	8
Moon	2009	Republic of Korea	Chloroquine	14	3.5	Not stated	660	3,881	1.6
Haghdoot	2006	Iran	Chloroquine	14	3.5	Not stated	2,555	12,337	7.4
High-dose primaquine (≥ 5.0 mg/kg total dose)									
Baird	1995	Indonesia	Chloroquine	27	10.0	Not stated	28	26	15.4
Baird	1995	Indonesia	Chloroquine (10 mg/kg)	27	10.0	Not stated	28	23	13.0
Fryauff	1997	Indonesia	Halofantrine	28	10.0	All doses	28	26	0.0
Fryauff	1997	Indonesia	Chloroquine	28	10.0	All doses	28	27	11.1
Wilairatana	1999	Thailand	Artesunate	14	7.0	Not stated	28	15	0.0
Wilairatana	1999	Thailand	Sulfadoxine–pyrimethamine	14	7.0	Not stated	28	19	0.0
Wilairatana	1999	Thailand	None	14	7.0	Not stated	28	17	0.0
Lacy	2002	Indonesia	Atovaquone/proguanil	14	7.0	Not stated	28	16	0.0
Silachamroon	2003	Thailand	Artesunate (5 days)	14	7.0	Not stated	28	142	0.0
Silachamroon	2003	Thailand	Artesunate (7 days)	14	7.0	Not stated	28	157	0.0
Dao	2007	Vietnam	Artesunate	7	5.3	All doses	28	28	3.6
Krudsod	2008	Thailand	Artesunate	11	5.5	Not stated	28	48	0.0
Krudsod	2008	Thailand	Artesunate	14	7.0	Not stated	28	52	0.0
Krudsod	2008	Thailand	Artesunate	7	7.0	Not stated	28	49	4.0
Pukrittayakamee	2010	Thailand	None	7	7.0	Not stated	28	33	6.0
Looareesuwan	1999b	Thailand	Atovaquone/proguanil	14	7.0	Not stated	84	35	5.7
Alving	1960	United States, Chesson	Chloroquine	56	8.0	Not stated	120	51	5.9
Alving	1960	United States, Chesson	Chloroquine	56	6.0	Not stated	120	40	10.0
Alving	1960	United States, Chesson	Chloroquine	98	7.0	Not stated	120	30	20.0

Contacos	1974	United States, Chesson	Chloroquine	56	6.0	Not stated	133	10	0.0
Martelo	1969	United States, Vietnam	Chloroquine	56	6.0	Not stated	180	21	28.6
Fisher	1970	United States, Vietnam	Chloroquine	56	6.0	Unsupervised	180	94	22.3
Clyde	1977	United States, Chesson	Chloroquine	7	7.0	All doses	293	11	0.0
Leslie	2008	Pakistan	Chloroquine	14	7.0	All doses	330	54	1.9
Leslie	2008	Pakistan	Chloroquine	56	6.0	All doses	330	68	5.9
Saint-Yves	1977	PNG	Chloroquine	14	5.3	All doses	365	10	0.0
Bunnag	1994	Thailand	Chloroquine	14	5.3	Not stated	540	86	1.2
Kaplan	1974	United States, Somalia	Chloroquine	21	5.3	All doses	895	207	4.3
Primaquine dose not stated									
Dunne	2005	India	Azithromycin	14	Not stated	Not stated	28	100	0.0
Dunne	2005	India	Chloroquine	14	Not stated	Not stated	28	97	0.9
Control arms (no primaquine)									
Dixon	1985	Thailand	Chloroquine		No primaquine		28	11	0.0
Pukrittayakamee	1994b	Thailand	Chloroquine		No primaquine		28	30	0.0
Baird	1995	Indonesia	Chloroquine		No primaquine		28	23	87.0
Baird	1995	Indonesia	Chloroquine		No primaquine		28	22	68.2
Looareesuwan	1999a	Thailand	Chloroquine		No primaquine		28	445	0.5
Pukrittayakamee	2000	Thailand	Chloroquine		No primaquine		28	21	0.0
Walsh	2004	Thailand	Chloroquine		No primaquine		56	10	80.0
Luxemburger	1999	Thailand	Chloroquine		No primaquine		63	69	55.1
Di Lorenzo	1953	United States, Korea	Chloroquine		No primaquine		90	46	50.0
Alving	1953	United States, Korea	Chloroquine		No primaquine		120	355	38.6
Alving	1960	United States, Chesson	Chloroquine		No primaquine		120	74	95.9
Yeshiwondim	2010	Ethiopia	Chloroquine		No primaquine		157	108	8.3
Gogtay	1999	India	Chloroquine		No primaquine		180	60	11.7
Rajgor	2003	India	Chloroquine		No primaquine		180	101	12.9
Leslie	2004	Pakistan	Chloroquine		No primaquine		270	212	40.6
Rowland	1999	Pakistan	Chloroquine		No primaquine		300	250	51.6
Rowland	1999	Pakistan	Chloroquine		No primaquine		300	100	49.0
Leslie	2008	Pakistan	Chloroquine		No primaquine		330	68	32.4
Adak	2001	India	Chloroquine		No primaquine		365	224	40.2
Yadav	2002	India	Chloroquine		No primaquine		365	723	8.6

Figure 1



Figure 2



Figure 3




Figure 4




Figure 5




Figure 6

